Microarray Analysis of Spinal Ischemia

Page 2 of 46

Abstract

Spinal ischemia is a frequent cause of paralysis. Here we explore the biological basis of ischemic preconditioning (IPC), the phenomenon in which a brief period of ischemia can confer protection against subsequent longer and normally injurious ischemia, to identify mediators of endogenous neuroprotection. Using microarrays, we examined gene expression changes induced by brief spinal ischemia using a rat balloon occlusion model. Among the nearly 5,000 genes assayed, relatively few showed two-fold changes, and three groups stood out prominently. The first group codes for heat shock protein 70, which is induced selectively and robustly at 30 min after brief ischemia, with increases up to 100-fold. A second group encodes metallothioneins 1 and 2. These mRNAs are increased at 6 and 12 hrs after ischemia, up to 12-fold. The third group codes for a group of immediate-early genes not previously associated with spinal ischemia: B-cell translocation gene 2 (BTG2), the transcription factors early growth response 1 (egr-1) and nerve growth factor inducible B (NGFI-B), and a mitogen-activated protein kinase phosphatase, ptpn16, an important cell signaling regulator. These mRNAs peak at 30 min and return to baseline or are decreased by 6 hrs after ischemia. Several other potentially protective genes cluster with these induced mRNAs, including small heat shock proteins, and many have not been previously associated with IPC. These results provide both putative mediators of IPC and molecular targets for testing preconditioning therapies.

Keywords: spinal cord; ischemia; preconditioning; Hsp70; metallothioneins; neuroprotection; microarrays

Mediators of Ischemic Preconditioning Identified By Microarray Analysis of Rat Spinal Cord

Jason B. Carmel¹, Osamu Kakinohana², Ruben Mestril³, Wise Young¹, Martin Marsala², Ronald P. Hart¹

¹W.M. Keck Center for Collaborative Neuroscience, Rutgers University 604 Allison Rd, D-251, Piscataway, NJ 08854

²Anesthesiology Research Laboratory-0818, University of California, San Diego

9500 Gilman Drive, San Diego, CA, 92093 ³Loyola University Medical Center, The Cardiovascular Institute,

2160 South First Avenue, Maywood, IL, USA

Correspondence: Ronald P. Hart W.M. Keck Center for Collaborative Neuroscience Rutgers University 604 Allison Rd, D-251 Piscataway, NJ 08854 USA Tel: 732-445-1783 Fax: 732-445-2063 e-mail: rhart@rci.rutgers.edu

Microarray Analysis of Spinal Ischemia

Page 3 of 46

Introduction

A common cause of spinal cord ischemia is cross-clamping of the aorta during repair of thoracoabdominal aneurisms. Clinical studies have demonstrated that the incidence of paraplegia in patients who underwent such procedures ranges between 0% and 40% depending on the series and patient risk factors (Cox et al., 1992; Verdant et al., 1995). In addition, several syndromes of vascular insufficiency have been described, including anterior spinal artery syndrome (Castro-Moure et al., 1997) and spinal cord compression (Ducker et al., 1984). Finally, spinal cord ischemia may participate in secondary cell death after traumatic injury (Mautes et al., 2000; Tator and Fehlings, 1991). Blood flow in the spinal cord falls dramatically after experimental injury and the post-traumatic ischemia correlates strongly with neurological loss (Tator and Fehlings, 1991). Taken together, these causes of spinal cord ischemia affect hundreds of thousands of people each year. The large number of people affected and the severity of their disability call for strategies to protect the spinal cord from ischemic damage.

Marsala and colleagues previously described a simple, reproducible, and clinically relevant rat spinal ischemia model employing balloon occlusion of the descending aorta (Taira and Marsala, 1996). Aortic occlusion causes a low blood flow state in the spinal cord. In this model 10 min of spinal ischemia leads to development of spastic paraplegia and a selective loss of interneurons in the intermediate zone of lumbosacral segments. Ischemic intervals shorter than 8 min have no long-term effect on motor function or histopathological appearance of the spinal cord. Here we use this model to investigate an endogenous form of neuroprotection called ischemic preconditioning (IPC). IPC describes the phenomenon that a short period of ischemia confers tolerance of a tissue to a subsequent longer period of ischemia. Rats were exposed either to brief ischemia or to sham surgery, various periods of normal perfusion (reflow), and then 10 Carmel et al.

Microarray Analysis of Spinal Ischemia

Page 4 of 46

min of ischemia. Locomotor scores were measured over the subsequent week. 3 min of ischemia protects rats at an early time after ischemia (30 min reflow) and a late time (24 hrs reflow) but not an intermediate time (2 hrs reflow). 6 min of ischemia provides protection only at 24 hrs of reflow, and this protection is greater than that afforded by 3 min IPC at the same reflow period (Cizkova et al.; accompanying manuscript).

The biphasic protection observed after 3 min ischemia has been observed in other preconditioning models (Shohami et al., 1987). Although the early and late phases of ischemic tolerance share common mechanisms, they also have significant differences. One important distinction is that while early tolerance does not require production of new proteins, delayed preconditioning does (Barone et al., 1998; Matsuyama et al., 2000). In keeping with this, cardiac preconditioning was abolished by the addition of the transcription inhibitor Actinomycin D (Strohm et al., 2002). By employing microarrays to show changes associated with brief ischemia, we focused our investigation on the late phase of ischemic preconditioning, which likely depends on mRNA changes.

Others have used genomic tools to provide insight into neuronal ischemia in general (Soriano et al., 2000; Jin et al., 2001; Majda et al., 2001; Jin et al., 2001) and ischemic tolerance in particular (Omata et al., 2002; Bernaudin et al., 2002). Previously we employed Affymetrix microarrays to characterize traumatic spinal cord injury (Carmel et al., 2001; Nesic et al., 2002). In order to better characterize the molecular mediators of spinal cord IPC, we used microarrays to survey mRNA changes after brief ischemia. In this study we used spotted oligonucleotidebased microarrays to survey gene expression differences between the spinal cords of rats with or without ischemic preconditioning. Selected results were validated using Q-RT-PCR. Our goal

Microarray Analysis of Spinal Ischemia

Page 5 of 46

was to identify possible mediators of the preconditioning effect that can be subjected to further testing to determine their role in IPC and their protective potential.

Carmel et al.

Microarray Analysis of Spinal Ischemia

Page 6 of 46

Material and Methods

All animal experiments were conducted according to protocols approved by the Institutional Animal Care and Use Committee of the University of California, San Diego.

Induction of spinal ischemia: Male Sprague-Dawley rats (300-365 g; Harlan Industries, Indianapolis IN) were used. A previously described technique was used to induce spinal cord ischemia (Taira and Marsala, 1996). Animals were anesthetized with 3% halothane in an O2/room air mixture (1:1) in an induction box and were maintained with 1-1.5% halothane delivered by an inhalation mask. A probe was inserted 6 cm into the rectum for core temperature measurements. Following anesthetic induction, a 2F Fogarty catheter was passed through the left femoral artery to the descending thoracic aorta so that the tip reached the level of the left subclavian artery. This level corresponds to a distance of 10.8-11.4 cm from the site of insertion. To measure distal blood pressure (DBP; i.e. below the level of occlusion), the tail artery was cannulated with a PE-50 catheter. The left carotid artery was cannulated with a 20-gauge polytetrafluoroethylene catheter for blood withdrawal. To induce spinal cord ischemia, the intraaortic balloon catheter was inflated with 0.05 mL of saline. Proximal hypotension (40 mm Hg) was maintained by withdrawing blood (10.5-11 cc) from the carotid artery. The efficacy of occlusion was evidenced by an immediate and sustained drop in the DBP measured in the tail artery. After ischemia, the balloon was deflated, and the blood was reinfused over a period of one min. After blood reinfusion, 4 mg of protamine sulfate was administered subcutaneously. Stabilization of the arterial blood pressure was then monitored for additional 10 min after which arterial lines were removed and wounds closed. In control animals the balloon catheter was placed into descending thoracic aorta but was not inflated. At the end of the survival period animals were terminally anesthetized with pentobarbital, cervical and lumbosacral spinal cord

Microarray Analysis of Spinal Ischemia

Page 7 of 46

segments were removed by hydroextrusion, and samples were immediately frozen in -70°C pentane.

Microarrays

Design: The 4,967 probes on our custom microarrays contain a collection of 4,854 oligonucleotides specific for 4,803 rat cDNA clusters purchased from Compugen, Inc. (Jamesburg NJ) and a set of 113 oligos designed and synthesized by MWG-Biotech AG (Ebersberg, Germany) based on a set of GenBank accession numbers selected by us. The probes, 65-70 nt in length, are standardized for melting temperature and minimal homology. All bioinformatics for the oligonucleotides are provided on our web site, http://www.ngelab.org.

Printing and Processing: Microarrays were printed on poly-L-lysine-coated glass slides using an OmniGrid microarrayer (GeneMachines, San Carlos CA) and quill-type printing pins (Telechem, Sunnyvale CA). Oligonucleotides were resuspended to 40 μM in 3X SSC and printed at 24°C with a relative humidity of approximately 50%. After printing, arrays were stored overnight and post-processed by standard procedures. Slides were stored at room temperature in a desiccator flushed with nitrogen and were used between three weeks and three months after printing.

RNA Preparation: Frozen lumbar spinal cords were suspended in ice-cold Trizol (Invitrogen, Carlsbad CA) and homogenized with a tissue grinder. Chloroform was added to the Trizol homogenate and a phase extraction performed. A small volume (0.5 ml) of the resulting aqueous phase was adjusted to 35% ethanol and loaded onto an RNeasy column (Qiagen, Valencia CA). The column was washed and RNA eluted following the manufacturer's recommendations. RNA was quantified by spectroscopy, with A₂₆₀/A₂₈₀ ratios at pH 8.0 between 1.9 and 2.1 for all samples. Samples of 6-min ischemia cord RNA and sham controls were

Carmel et al.

Microarray Analysis of Spinal Ischemia

Page 8 of 46

subjected to capillary electrophoresis on an Agilent (Palo Alto CA) 2100 Bioanalyzer; all samples demonstrated sharp ribosomal RNA bands (not shown).

The same RNA preparations were used for both microarray and Q-RT-PCR assays, except that each control channel in the microarray assays represent a "reference" pool of the control RNAs (Yang and Speed, 2002). Initial studies used 6 sham control rats—half received sham surgery 30 min before sacrifice, the others 24 hrs before. Real-time PCR experiments showed no differences in gene expression between these two control groups for HSP70, metallothionein, GAPDH, and all other genes measured (not shown). Under the presumption that time-matching sham and control animals was unnecessary, equivalent amounts of RNA were pooled from all sham animals, and the same pooled reference RNA was used for all microarray experiments.

Hybridization target was prepared using the Genisphere 3DNA dendrimer system (Stears et al., 2000; Genisphere, Inc., Hatfield PA). Two micrograms of total cellular RNA were reversetranscribed from a "capture-sequence"-containing oligo-d(T)₁₈ primer using Superscript II (Invitrogen) and then alkaline hydrolyzed to destroy RNA. Automated hybridizations were performed using a Ventana Discovery System (Ventana Medical Systems, Tuscon AZ) following protocols designed by us. The sequence-tagged target was hybridized for 12 hrs at 58°C, and microarrays were washed twice in 2X SSC for 10 min at 55°C and 2 min at 42°C. Fluorescent dendrimer was then applied and incubated at 55°C for 2 hrs. The microarrays were washed with 2X SSC for 10 min at 55°C and then removed from the instrument and washed vigorously three times for one min each in Reaction Buffer (Ventana Medical Systems) and then once in 2X SSC for one min. Arrays were spin-dried in a centrifuge and scanned on an Axon GenePix 4000B (Axon Instruments, Union City CA).

Microarray Analysis of Spinal Ischemia

Page 9 of 46

Dye flip controls were performed in a separate experiment. A group of 7 microarrays were hybridized with Ambion rat brain and liver control RNAs, with 3 arrays labeling liver RNA with Cy3 and 4 arrays labeling liver RNA with Cy5. We examined the pairwise Pearson correlation coefficients for the valid observations on each slide (-4,950) to determine data reproducibility. No difference was found between correlations within each dye group [0.931 ± 0.013 (3) and 0.963 ± 0.003 (4)] and correlations from one dye group to the other [0.925 ± 0.011 (12); each listed as mean \pm s.e.m. (n)]. Therefore, we concluded that the inclusion of dye flips within our experimental design was not necessary under these conditions.

Data Analysis: Image files were processed using Axon GenePix 4.0 software, resulting in text files containing median fluorescence intensities, median local backgrounds, and flags of the few spots with overlaid background. Results were imported to the public microarray database BASE (Saal et al., 2002). Normalization and data analysis were conducted in GeneSpring (Silicon Genetics, Redwood City CA), using a custom ODBC interface to the BASE database (DeLong and Hart, unpublished). We used the Lowess method of normalization (Yang et al., 2002). The ratio of signal intensities was calculated only if the spot was not flagged, and replicates were averaged.

Statistical analysis: To better elucidate groups of changed genes we employed k-means clustering, beginning with a filtered group of genes (see text). We employed the GeneSpring Standard Correlation as our similarity metric. The reproducible difference between mean ratios and a ratio of unity (expressed as the t-test p value) was assessed using GeneSpring's Global Error Model of replicates, an implementation of the Rocke-Lorenzato model. Carmel et al.

Microarray Analysis of Spinal Ischemia

Ouantitative Real-time PCR

Page 10 of 46

We confirmed selected microarray results by comparison with relative mRNA levels obtained by quantitative reverse transcription PCR (Q-RT-PCR) using selected gene-specific primer pairs (Table 1). RNA was reverse transcribed with SuperScript II (Invitrogen, Carlsbad CA) and random primers as suggested by the manufacturer. The PCR reactions were carried out using 20 ng of cDNA, 67 nM of each primer, and SYBR Green master mix (Applied Biosystems, Foster City CA) in 10 µl reactions. Levels of Q-RT-PCR product were measured using SYBR Green fluorescence (Wittwer et al., 1997; Ririe et al., 1997) collected during real-time PCR on an Applied Biosystems 7900HT system. A control cDNA dilution series was created for each gene to establish a standard curve. Each reaction was subjected to melting point analysis to confirm single amplified products. Reactions were run in duplicate, and results were averaged. Each value was normalized to GAPDH to control for variations in amount of input cDNA. Foldchange values represent a mean of four ischemic samples divided by the mean of the six sham controls described above. Change between ischemic and sham animals was determined significant by Student's t-test using a p value less than 0.05. *Northern Blot*

A separate group of rats was used for Northern blot experiments. Animals were subjected to 6 min of spinal cord ischemia as described above. At the end of the survival period (4, 18, or 24 hrs), rats were sacrificed and their spinal cords collected. Cervical segments of the spinal cord (C2-C5; non-ischemic) were pooled (three segments/extraction) as were the lumbar segments (L2-L5; ischemic). Total RNA was extracted using guanidine thiocyanate extraction buffer (Puissant and Houdebine, 1990). RNA was separated by electrophoresis in 1% agaroseformaldehyde gels, transferred onto nitrocellulose membranes, and hybridized with a 3'-end

Microarray Analysis of Spinal Ischemia

Page 11 of 46

labeled hsp70 oligonucleotide probe (2-5 X 10⁶ cpm/ml buffer) at 42°C overnight. The blot was washed to high stringency and autoradiographed with two intensifying screens (DuPont, Wilmington DE) at -70°C for 1-14 days. Each blot was stripped and rehybridized with a control 18S oligonucleotide rRNA probe. Bands were quantified with an MCID analysis system (Imaging Research Inc., St. Catharines, Ontario, Canada) and results were expressed in arbitrary optical density units. Values were corrected for loading and expressed as fold change over shamoperated controls.

gene to amplitud a standard entror. Each reaction was subjected to radiate point stalpate to condima single any (Prod produce. Productors was two in digitizate, and readly was startent back value and no reduced in (CARDIT in tenter) for variations in anomin. If input aDNA. For change values represent a times of fair indentity remained intelled by the mean of the first alma compose generated above. Change harmon indentity and start and start and was described programs for States is trained in the startent indentity and start and start of the first alma eigenformer to States in a start and a program indentity and start and start and start and the start of the start eigenformer to States in the start of the startent indentity and start and the start of the start of the start of the start of the startent indentity and start and start and the start of the start o

A segment group of rate west weat for Northern blue appenditions. Animult were addjorte to 6 gene of second contention of described above. At the end of the nervical partiel (4, 18, or 7.4 km), new were satisficed and their relation or the collected. Cervical argumate of the spinol of (C. C. C. C. particulation), were pooled (their segmentation collected. Cervical argumate of the spinol (1, 2-1, 5) induced). Total RMA was entranced using particular this particle ballier (C. S. C. S. particulation). Total RMA was expressed using particular the induced ballier (C. S. S. S. particulation (1990). RMA was expensed by observed by contemporate in 1% agarents

Carmel et al.

Results

Microarray Analysis of Spinal Ischemia

Page 12 of 46

To survey mRNA changes induced by brief ischemia, we applied ischemic and sham control samples to oligonucleotide microarrays. Animals (n=4 at each time point) were exposed to either 3 min or 6 min of spinal cord ischemia and were allowed to survive for various times: 30 min, 6 hrs, 12 hrs, or 24 hrs. RNA from individual ischemic cords was compared to reference pooled RNA from sham controls. Results were expressed as a fold change ratio of net hybridization signal for ischemic samples to sham controls.

The results of the 3-min ischemia and 6-min ischemia microarray experiments are graphed in Figs. 1A and 1B, respectively. The relative ischemia/sham ratio is plotted on the yaxis against the time of reflow after brief ischemia on the x-axis. Each plotted line represents the result from a single oligonuc leotide probe on the microarray. Of the probes assayed, few showed large changes, and two groups stood out prominently. In the 3-min ischemia experiment three mRNAs were found to be strongly increased over sham controls at 30 min of reflow (Fig. 1A). All three of the probes showing strong differences at this time point are specific for the same protein, HSP70. Two probes (hsp70 and hsp70.1) detect the same mRNA; another probe (hsp70.2) hybridizes with ar HSP70-encoding mRNA having a different 3' untranslated region (Table 2). For animals that received 3 min of ischemia, hsp70 mRNA was increased maximally at 30 min of reflow, had smaller increases at 6 and 12 hrs, and returned to sham baseline levels by 24 hrs. The three hsp70 probes also showed the largest ratios following 6 min of ischemia (Fig. 1B). 6 min preconditioned spinal cords showed even greater ratios of hsp70 at 30 min than the 3-min ischemia/30-min reflow group, and levels continued to rise at 6 and 12 hrs before declining at 24 hrs.

Microarray Analysis of Spinal Ischemia

1

Page 13 of 46

We measured the same RNA preparations by Q-RT-PCR to confirm microarray results (Tables 3 and 4 and Figs. 2B and 3B). Hsp70 mRNA changes were far greater by Q-RT-PCR than by microarray, consistent with the superior dynamic range of Q-RT-PCR. In 3-min ischemia animals, hsp70.1 and hsp70.2 mRNA levels rose to ~25 times the levels of sham-operated controls at 30 min after preconditioning (Fig. 2B and Table 3). These levels fell over the course of one day and were not significantly different from sham by 24 hrs. After 6-min of ischemia, spinal cords showed robust induction of hsp70 at 30 min with further rises at 6 and 12 hrs to a peak of ~100-fold change from sham animals (Fig. 3B and Table 4). As with the microarray results, 6 min of ischemia produced more intense and prolonged increases in hsp70 mRNA than did 3 min of ischemia.

To test whether increased hsp70 mRNA was a local response to ischemia or whether it might be elevated elsewhere in the spinal cord, a Northern blot was performed on spinal cord samples of a separate group of animals after 6 min of ischemia or sham surgery. Lumbar (L2-5) and cervical (C2-5) spinal cords were collected, RNA from 3 animals was extracted, pooled, and analyzed by Northern blot (Fig. 4A). Lanes A-C contain RNA from spinal cords that received 6 min ischemia and lanes D-F were run with RNA from sham-operated rats. Animals were sacrificed at 4 hrs (lanes A and D), 18 hrs (lanes B and E), and 24 hrs (lanes C and F) after ischemia. Northern blot results are shown in Fig. 4B and quantifications are expressed as foldchange from sham controls. A single band of hybridization was observed under all conditions, suggesting that the Hsp70 mRNA was not alternatively spliced or otherwise changed in sequence throughout the experiment (although Hsp70 mRNA is normally unspliced). Robust accumulation (-25-fold) of hsp70 mRNA was seen 4 hrs after preconditioning in the lumbar spinal cord, but no change was seen at 18 or 24 hrs. Cervical cord segments showed no induction Carmel et al.

Microarray Analysis of Spinal Ischemia

Page 14 of 46

of hsp70 mRNA at any of the reflow time points. These results confirm that hsp70 mRNA induction after 6 min is robust and appears limited to the ischemic areas of spinal cord. Hsp72like immunoreactivity was detected in neurons of the superficial dorsal horn following 3 min of ischemia (Cizkova et al., accompanying manuscript). A 6 min period of ischemia extended staining to neurons of the intermediate zone, consistent with a protective function in these cells.

Another group of microarray probes, increased at 6 and 12 hrs, stand out prominently in Figs. 1A and 1B. In the 3-min ischemia experiment, only one of these stood apart (Fig. 1A), whereas three showed robust increases in the 6-min ischemia group (Fig. 1B). The three probes detect metallothioneins- (MT-) 1 and 2 mRNAs. In both 3-min and 6-min ischemia groups, MT-1 and MT-2 mRNA levels were not increased above sham at 30 min of reflow. Levels rose sharply by 6 hrs of reflow and remained elevated at 12 hrs before falling towards baseline by 24 hrs. As with hsp70, MT-1 and MT-2 mRNA levels were more highly increased following 6 min of ischemia than with 3 min.

Like hsp70, MT mRNAs also showed greater fold-changes by Q-RT-PCR than by microarrays (Tables 3 and 4) MT-1 mRNA levels rose more than 5-fold at 6 hrs after 3 min of ischemia; after 6 min of ischemia MT-1 rose more than 13-fold over sham controls. MT-2 showed a similar time course, increasing more than 3 times the levels of sham controls at 6 hrs after 3 min ischemia, while 6 min of ischemia induced more than 10-fold change at the same time point.

In order to select results from the microarray experiments with reliably altered ratios, we filtered the results using three criteria: minimum expression, minimal fold-change values, and ratios reproducibly different from unity. Probes had to have signal intensity twice array median background in at least 3 of 4 time points. The hybridization ratio had to be at least 2-fold higher

Microarray Analysis of Spinal Ischemia

Page 15 of 46

or lower than sham controls at one or more time points. Finally, the ratios had to be different from unity at one or more time points as measured by Student's t-test (p < 0.05; uncorrected for multiple comparisons; GeneSpring's Global Error Model). Of these filters, the 2-fold ratio filter was by far the most restrictive (not shown). The probes (n=5) that passed the above criteria for the 3-min experiment are the three probes for hsp70 and two for MT. These results are listed in Table 3, and are graphed in Fig. 1C. The probes that passed the filtering criteria for the 6-min ischemia (n=31) are listed in Table 4 and are graphed in Fig. 1D.

31 probes from the 6-min ischemia experiment passed our filtering criteria. In order to partition groups of differentially affected mRNAs, we employed k-means clustering on this subset of genes. The goal was to find relationships between members of this filtered list in hopes grouping mRNAs by common biological function or regulatory response. Clustering was carried out using 3, 5, 9, or 15 starting clusters and the Standard Correlation metric (see Methods). Setting k=5 gave the highest explained variability and is pictured in Fig. 3A. Multiple iterations of the clustering algorithm produced essentially the same clusters each time (not shown).

Of the five k-means clusters, three represent groups of probes with ratios increased after brief ischemia. These three clusters include hsp70 (Cluster 1), MT (Cluster 2), and a group of immediate early genes (IEGs; Cluster 3). Three other mRNAs clustered with the hsp70 group (Cluster 1): heme oxygenase-1, NSF attachment protein, and activating transcription factor 3 (ATF3). Clustered with MT (Cluster 2) are two heat shock proteins: crystallin αB (cryab), and heat shock 27 (hsp27, two probes), as well as five other mRNAs: cyclin-dependent kinase inhibitor 1A (Cdkn1a, a.k.a. p21^{WAF}), a UV radiation-activated gene (U96), TBP interacting protein (Tip120B), ornithine decarboxylase antizyme inhibitor (oazi), and synaptotagmin 7 (syt7). Four mRNAs showed a pattern peaking at 30 min after ischemia followed by decreasing

Carmel et al.

Microarray Analysis of Spinal Ischemia

Page 16 of 46

ratios at later times, typical of IEGs (Cluster 3). This group is composed of B-cell translocation gene 2 (BTG2), early growth response-1 (egr-1), protein tyrosine phosphatase, non-receptor type 16 (Ptpn16), and immediate early gene transcription factor NGFI-B (Nr4a1). Two additional clusters exhibited decreases in mRNA levels following ischemia (see Table 4).

Selected mRNAs in each cluster of the 6-min ischemia experiment were measured by Q-RT-PCR. The results of these measurements are presented in Table 4 and are graphed in Fig. 3B. The graphs are split into the corresponding k-means clusters of microarray results. The Q-RT-PCR results of the mRNAs with increased expression show strong similarity to microarray measurements, with the exception of syt7. Of the decreased mRNAs only MPZ showed similar results between microarray and Q-RT-PCR measurements. We, therefore, consider these results less reliable than the results of induced genes (see Discussion).

We also measured for mRNA expression by Q-RT-PCR and include the results with the other IEGs. The microarray probe for fos has been found to interact with the Genisphere Cy5 dendrimer probe "capture sequence" (Hart and Getts, unpublished observations) and was excluded from analysis as a false positive. However, we measured for mRNA levels because it was implicated in spinal cord IPC previously (Yang et al., 2000). Fos mRNA elevation (13-fold) was greater and more sustained than other IEGs measured in this study (Table 4 and Fig. 3B).

We asked whether the three clusters with increased ratios in the 6-min ischemia experiment might have homologous patterns in the 3-min ischemia experiment. The hsp70 group (3 probes) and a MT group (2 probes) are contained in the filtered set of probes from the 3-min results (Fig. 2B). However, the IEGs and other genes identified in the 6-min clustering fell below our arbitrary 2-fold ratio restriction. To test whether similar genes clustered in the 3-min experiment, we first created a set of less stringently filtered genes by setting the fold change

Microarray Analysis of Spinal Ischemia

Page 17 of 46

cutoff at 1.5 (n=159). K-means clustering with this group identified an hsp70 cluster, a MT cluster, and a cluster with several IEGs (data not shown). However, the explained variability of this clustering was low compared to that of the stringently filtered 6-min k-means, and the patterns were less easily distinguishable on visual inspection. The magnitude of effects following 6 min of ischemia was more pronounced and the patterns of response were more easily partitioned by the k-means algorithm into meaningful groups than the results of the 3 min ischemia.

To better isolate the hsp70, MT, and IEG groups in the 3-min data, we employed an "anchor gene" approach (Carmel et al., 2001). This clustering technique involves handpicking a gene of interest and then using the time series of that gene to find close correlates in hopes that retrieved genes might also be biologically meaningful or coordinately regulated. The Standard Correlation metric was used with a correlation coefficient of 0.90. Representative anchor genes from Clusters 1-3 (hsp70, MT, and egr-1 respectively) of the 6-min clustering were used to find close correlates in the 3-min data. We anticipated that of the 159 genes in the filtered subset, each anchor would more likely be paired with genes that clustered together in the 6-min results. This held true without exception. The microarray results of these correlations are graphed in Fig. 2A, and the O-RT-PCR results in Fig. 2B; both sets of results are included in Table 3. The temporal pattern of each hsp70 probe was highly correlated with the other two, as was the case for the three MT probes. In addition, the pattern for cryab was also associated with each MT probe; these genes were clustered together in the same 6-min k-means. For egr-1, the gene whose expression correlated significantly was ptpn16. This pairing was also found with the 6-min kmeans clustering. Thus, similar clusters were found in both the 3-min and 6-min ischemia experiments.

Carmel et al.

Discussion

Microarray Analysis of Spinal Ischemia

Page 18 of 46

Investigation of ischemic preconditioning in the rat spinal cord may reveal molecular mechanisms that can be exploited to protect people from paralysis after aortic aneurism repair or spinal contusion injury. Although spinal cord IPC has been demonstrated in experimental models, the basis for the tole ant state has not been well elucidated. Here we employ microarrays to survey gene expression associated with IPC and to identify target genes for future study. Our studies of gene expression after short ischemia identify several genes and gene families that are changed significantly. These include hsp70, MT, small heat shock proteins, IEGs, and other possible neuroprotective agents, including several not previously reported.

Spotted oligonucleotide microarrays have been demonstrated to be a reliable technique for assessing large number of mRNAs (Hughes et al., 2001; Wang et al., 2003). Most microarray results were validated by Q-RT-PCR measurements, and expression profiles generally have similar patterns by the two measures. Microarrays tended to underestimate changes, an observation that has also been made by others (Rajeevan et al., 2001). All microarray results showing 3-fold or greater changes were validated. All increased genes, except synaptotagmin 7, were validated by Q-RT-PCR. Several probes showed divergent results, and these were mostly the decreased genes, including Ttpa, IkB, GlyRA1, and MRG-3. Of the decreased genes only MPZ showed similar (although not statistically significant) changes by Q-RT-PCR. The reasons for this disparity are puzzling—results such as these would normally be indicative of microarray dye-specific false signals. However, our dye flip experiments showed high correlation coefficients between dye flipped pairs (see Methods).

Heat shock protein 70. The greatest increases were seen in hsp70 mRNA, up to 100-fold higher after 6 min ischemia than sham controls. The inducible heat shock protein 70 (HSP70) is

Microarray Analysis of Spinal Ischemia

Page 19 of 46

a molecular chaperone that aids in the folding of nascent proteins and binds proteins during times of cell stress, including hyperthermia and ischemia (Mestril and Dillmann, 1995). HSP70 was first identified in Drosophila exposed to hyperthermic preconditioning that protected against a lethally hot environment (Arrigo and Welch, 1987; Tomasovic et al., 1985). Increases in HSP70 have been associated with models of IPC, including spinal cord IPC (Matsuyama et al., 1997; Matsumoto et al., 2001). Other interventions that protect the spinal cord, including whole body hyperthermia (Zhang et al., 2000), local cooling (Motoyoshi et al., 2001), and pharmacological stress (Perdrizet et al., 2002) all increase HSP70 levels. Finally, in models of cerebral ischemia, overexpression of HSP70 protects neurons from ischemic insult (e.g., Kelly et al., 2001; Hoehn et al., 2001), while loss of HSP70 abrogates the conditioning effect (Nakata et al., 1993). In a companion acticle, Marsala and colleagues report an analysis of HSP70 expression and localization after brief spinal ischemia (Cizcova et al., accompanying manuscript).

Metallothioneins. Two other mRNAs that show robust increases following brief ischemia are MT-1 and MT-2. Metallothioneins are a family of cysteine-rich, low molecular weight proteins that bind transition metals, such as zinc and copper (Hamer, 1986). MT-1 and MT-2 are induced by heavy metals, oxygen free radicals, glucocorticoids, cytokines, and immediate early genes (Palmiter, 1998). MTs have been proposed as detoxifying agents of reactive metals and free radicals (Liu et al., 1991), both of which contribute to ischemia-induced cell damage (Chan, 1996). MT-1 and MT-2 are induced robustly by ischemia, including cerebral ischemia (Sharp et al., 1993; Gerlai et al., 2000; Ebadi et al., 1995), and MT has been identified as an ischemia-induced gene by other genomic screens, including serial analysis of gene expression (Trendelenburg et al., 2002) and microarrays (Onody et al., 2003). MT-1 and MT-2 have also been implicated in the delayed phase of ischemic preconditioning of the heart (Chen et al., 1997) and brain (Emerson et al., 2000)

Page 20 of 46

Microarray Analysis of Spinal Ischemia

Carmel et al.

Several groups have examined the effects of MT gain- and loss-of-function to elucidate its role in cellular protection. Induction of MT by application of transitional metals protects the heart against oxidative damage (Satoh et al., 1988) and human primary CNS cultures against irradiation damage (Cai et al., 2000). Cardiac myocytes overexpressing MT-1 were protected from ischemia by inhibition of the cytochrome c-mediated apoptotic pathway (Wang et al., 2001). van Lookeren Campagne and colleagues (1999) compared the effects of transient middle cerebral artery occlusion (MCAO) in transgenic mice that overexpress MT-1 (Iszard et al., 1995) and wild-type mice. Lesion volume and sensorimotor deficits were significantly decreased in MT-1 overexpressing mice compared to controls. In loss-of-function studies, repression of MT exacerbates cell damage. In the mouse model of familial amyotrophic lateral sclerosis that lacks superoxide dismutase, further deletion of MT-1 and MT-2 by crossbreeding resulted in earlier onset of clinical signs and death. Using the MT-1 and MT-2 double knockout (KO) mice, Trendelenberg and colleagues (2002) found KO mice had approximately three-fold larger cerebral infarcts and significantly worse neurological outcome than wild-type controls in response to transient ischema. These studies substantiate a cell protective role for MT.

Although hsp70 and MT induction constituted the most prominent mRNA changes that we observed in these experiments, brief ischemia affected other genes as well. We found the use of k-means clustering instructive in trying to group these genes. Several clusters included genes known to have similar function, suggesting that the groupings may follow biological likeness. *Genes Clustering With MT*. Grouped in the same cluster as MT were the small heat shock proteins hsp27 and αB crystallin (cryab). These two genes encode proteins that assemble

Microarray Analysis of Spinal Ischemia

Page 21 of 46

into chaperone complexes, which bind and protect proteins at times of cell stress (Dillmann, 1999). Cryab, first characterized as a major component of the vertebrate lens, is involved in many cellular processes, including oxidative stress responses in the heart and lung, cellular differentiation in the eye, and a variety of neurodegenerative disorders (Dillmann, 1999). Striated muscles, including the heart, express high levels of cryab (Iwaki et al., 1990). Overexpression of cryab protects myocytes from ischemia and also provides cardioprotection (Martin et al., 1997). Mice expressing a mutated form of the protein show increased damage to myocytes made ischemic (Martin et al., 2002).

Brief ischemia also induced the small HSP, hsp27, in the spinal cord. Hsp27 is induced by multiple cell stresses, including heat shock, ischemia, and seizures (Dillmann, 1999). As with αB crystallin, hsp27 expression in the stressed brain is primarily localized in astrocytes and rises more slowly and for longer periods of time than hsp70 (Akbar et al., 2001). Gain- and loss-offunction studies point to a protective role of hsp27. In a neuronal cell line and primary neuronal cultures, overexpression of hsp27 protected against exposure to heat shock and withdrawal of nerve growth factor (Wagstaff et al., 1999). Overexpression of hsp27 also protects cardiac myocytes against simulated ischemia (Martin et al., 1999). The same adenoviral vector encoding an hsp27 antisense oligonucleotide significantly decreased HSP27 levels and increased injury in cultured myocytes (Martin et al., 1999). Hsp27 also appears to play a key role in sensory neuron survival after axotomy or neurotrophin withdrawal (Lewis et al., 1999). Finally, Akbar and colleagues recently showed that mice overexpressing human hsp27 were protected from damage to hippocampal neurons due to kainate-induced seizures (Akbar et al., 2003). Identification of hsp27 mRNA increases following IPC is suggestive of a protective role in the spinal cord as well. Carmel et al.

Microarray Analysis of Spinal Ischemia

Page 22 of 46

The Immediate-Early Gene Cluster. Another group of genes revealed by k-means clustering, Cluster 3, includes four immediate-early genes: B-cell translocation gene 2 (BTG2), the transcription factors early growth response 1 (egr-1) and nerve growth factor inducible B (NGFI-B), and a mitogen-activated protein kinase phosphatase, ptpn16, an important cell signaling regulator. Egr-1 and ptpn16 also cluster together in the 3 min ischemia cluster. This cluster of genes shows an expression pattern of early induction followed by either return to baseline or repression at 6 hrs and later time points. The expression profile of these genes and their known function identifies them as possible regulatory genes that may affect downstream changes.

BTG2 was originally identified as a transcript induced by p53 in response to genotoxic stress (Rouault et al., 1996). Several studies also point to a role for BTG2 in neuronal differentiation. Similar to eg 1 and NGFI-B, BTG2 levels are increased in PC12 cells after induction of differentiation by NGF (Bradbury et al., 1991). BTG2 is expressed during the production of postmitotic neurons and is considered a marker of neuronal birth (Iacopetti et al., 1999). Importantly, expression of BTG2 appears to protect differentiated neural cells from apoptosis, as antisense oligonucleotides to BTG2 trigger programmed cell death (el-Ghissassi et al., 2002). The increased expression of several NGF-induced genes in this assay points to common mechanisms, and the protective role of BTG2 make it a promising target for future study.

Egr-1 (also known as NGFI-A, krox-24, or zif268) is a transcription factor and an immediate early gene (for review see Beckmann and Wilce, 1997). Egr-1 is induced in the rat brain by a large number of stresses, including glutamate/NMDA stimulation (Beckmann et al., 1997), long-term potentiation (Worley et al., 1991), focal traumatic brain injury (Honkaniemi et

Microarray Analysis of Spinal Ischemia

Page 23 of 46

al., 1995), and a variety of cerebral ischemia models (Abe et al., 1991; Collaco-Moraes et al., 1994). Egr-1 was also shown to be elevated in the spinal cord in response to noxious peripheral stimulus (Lanteri-Minet et al., 1993; Wisden et al., 1990) and sciatic nerve lesion (Herdegen et al., 1993). Recently, Rybnikova and colleagues (2002) showed that mild hypoxic preconditioning increased the level and duration of egr-1 expression in the rat brain following severe cerebral hypoxia. Other authors suggest that prolonged egr-1 expression after ischemic insult is associated with delayed neuronal degeneration (Honkaniemi and Sharp, 1996; Honkaniemi et al., 1997). The egr-1 gene codes for a zinc finger nuclear phosphoprotein that binds to GC-rich sequences in the promoter region to affect transcription of a diverse set of genes (Beckmann and Wilce, 1997). These include genes with potential protective roles, such as platelet-derived growth factor (Khachigian et al., 1996), transforming growth factor B (Khachigian et al., 1996), and NGFI-B (Williams and Lau, 1993). Some genes modulated by egr-1 may have deleterious effects on neuronal survival. These include NMDAR1 (Bai and Kusiak, 1995), tumor necrosis factor (Kramer et al., 1994), and two prothrombotic genes: tissue factor (Cui et al., 1996) and thrombospondin 1 (Shingu and Bornstein, 1994). Thus, whether egr-1 plays a protective or deleterious role may depend on the timing of its expression and its relationship to other transcriptional events, particularly those regulated by other IEGs.

NGFI-B was found in the same genomic screen as egr-1 (NGFI-A) of PC12 cells exposed to NGF (Milbrandt, 1988), and k-means clustering paired the two genes in this study as well. NGFI-B has a zinc finger domain and belongs to the thyroid/steroid receptor family. It is an immediate early gene that is stimulated by growth factors (Hazel et al., 1988), depolarization (Yoon and Lau, 1993), and seizures (Watson and Milbrandt, 1989). The pattern of induction by hypoxia (Gubits et al., 1993), global ischemia (Neumann-Haefelin et al., 1994), and focal Carmel et al.

Microarray Analysis of Spinal Ischemia

Page 24 of 46

ischemia (Lin et al., 1996) parallels those of other immediate early genes (Johansson et al., 2000). NGFI-B is known to regulate expression of corticotropin-releasing factor (CRF), vasopressin, oxytocin, and steroid 21-hydroxylase in vitro (Chan et al., 1993; Wilson et al., 1993; Wilson et al., 1991) all of which may be increased by stress. Although this gene is increased at times of stress and likely induces other stress-related genes, how NGFI-B might participate in neuroprotection remains to be elucidated.

In addition to egr-1, ptpn16 (a.k.a. mitogen-activated protein kinase phosphatase-1) also shows induction with both 3 and 6 min of ischemia. This gene encodes a dual specificity protein phosphatase that acts on tyre sine and threonine residues of mitogen-activated protein (MAP) kinases, inactivating the kinases (Alessi et al., 1993; Sun et al., 1993). Phosphorylation of MAP kinases is a key regulatory step in cell signaling, particularly during times of stress (for review see Irving and Bamford, 2002). Multiple stressors induce ptpn16, including oxidative stress, heat shock, seizures, and brain ischemia (Keyse and Emslie, 1992; Boschert et al., 1998; Wiessner et al., 1995). Two genomic screens identified this gene as induced by focal cerebral ischemia (Soriano et al., 2000) and hypoxic preconditioning (Bernaudin et al., 2002). Of the MAP kinase families, ptpn16 has stronger affinity for p38 and JNK than ERK (Camps et al., 2000). JNK and p38 signaling has several effects on cell survival, but most reports suggest deleterious effects of these pathways on neuronal survival (Maroney et al., 1999; Chihab et al., 1998). Thus, by inhibiting these pathways increased ptpn16 expression would likely enhance neuronal survival. Although the fos prope was excluded from microarray results because of cross reactivity with the labeling molecule (see Results), fos mRNA levels were assayed by Q-RT-PCR and

found to be the most highly induced of the IEGs. In brain ischemia paradigms, fos protein appears to be induced in neurons more resistant to ischemia (e.g. hippocampal CA3 neurons)

Microarray Analysis of Spinal Ischemia

Page 25 of 46

than in the more susceptible CA1 neurons (Johansson et al., 2000; Nowak, Jr. et al., 1990). Fos mRNA is also induced by short ischemic periods that are protective in brain IPC models (Truettner et al., 2002). Marsala and colleagues have shown that Fos protein was elevated by 6 min of spinal cord ischemia (Yang et al., 2000). The protein expression peaked at 2 hrs, and the expression at 4 hrs was limited to the susceptible interneurons in laminae V-VII. The spatial correlation of protein expression with protection and the robust, early, and sustained mRNA expression make fos an IEG worthy of further study.

Another transcription factor, activating transcription factor 3 (ATF3), is robustly induced (8-fold by Q-RT-PCR) at 30 min after 6 min of ischemia and remains elevated until returning to baseline by 24 hrs (Figs. 3A and 3B, Table 4). ATF3 is a member of the CREB family of transcription factors, which recognizes the cyclic AMP response element (CRE) site and forms dimers by binding at the leucine zipper region. ATF3 represses transcription as a homodimer (Chen et al., 1994) and activates transcription as a heterodimer with jun (Hai and Curran, 1991; Chu et al., 1994). ATF3 is induced in a variety of stressed tissues (reviewed in Hai et al., 1999), including the ischemic heart (Yin et al., 1997) and post-seizure brain (Chen et al., 1996). ATF3 is strongly induced by sciatic nerve lesion in dorsal root ganglia and spinal motor neurons (Tsujino et al., 2000). Overexpression in heart (Okamoto et al., 2001), pancreas (Allen-Jennings et al., 2001) and liver (Allen-Jennings et al., 2001) shows detrimental effects in these organs. Whether ATF3 may be acting as a functional activator or repressor of transcription in IPC remains to be investigated, but its marked induction and association with cell stress make it an enticing target for further study.

Comparison of 3 vs. 6 min of IPC. While 3 and 6 min IPC treatments have somewhat differing protective outcomes (see accompanying manuscript), most mRNA effects were similar

Carmel et al.

Microarray Analysis of Spinal Ischemia

Page 26 of 46

in the two models, with differences in magnitudes. The clustering of MT and αB crystallin was conserved between the 3-min and 6-min IPC experiments, and pairing of the IEGs egr-1 and ptpn16 was similarly conserved. In addition, the similarity of the clusters resulting from the 3min ischemia and the 6-min experiments implies that increasing the length of conditioning ischemia may modulate the amplitude, rather than the mechanisms, of the neuroprotective effect. 6 min of spinal ischemia induces similar changes in gene expression as 3 min, but the changes are more robust.

Summary. Most of the mRNA changes caused by brief ischemia of spinal cord appear to have potentially beneficial effects. The genes that are activated by brief ischemia may affect all stages of IPC, including signal transduction (e.g. ptpn16), transcription (e.g. ATF3, fos, egr-1), and effectors of neuroprotection (e.g. HSPs and MT). This study increases the number of candidate neuroprotective genes. It also places changes in suspected mediators (e.g. hsp70) in the context of overall mRNA changes. It is likely that some of these changes will participate directly in the neuroprotective state while others will not. Among the criteria important for selecting potential protective genes for study are the magnitude of change, the known biological function of the gene, and the novelty of the association. Hsp70 mRNA shows enormous induction by preconditioning (up to 100-fold) and the product has proven beneficial effects in CNS ischemia. So hsp70 is an attractive target, although it is the most widely studied gene in spinal ischemia and preconditioning. MT-1 and MT-2, on the other hand, have not been studied in spinal cord IPC, although their protective effects in brain ischemia are well documented. The magnitude of the mRNA induction of these genes and their dual roles in heavy metal binding and free radical scavenging make them very appealing targets for study in this system. Among the more novel genes whose expression is induced by brief ischemia are the IEG transcription factors, including

Microarray Analysis of Spinal Ischemia

Page 27 of 46

fos, egr-1, and ATF3. Although induced more moderately than hsp70 and MT, these genes may serve as gatekeepers to transcriptional events that confer neuroprotection. Identification of these responses to brief ischemia provides good justification for detailed, mechanistic studies with this limited set of genes.

The molecular mediators found by study of IPC may appear to have the greatest clinical applicability in the prevention of paralysis that occurs due to cross-clamping during aorta surgery. Our study provides a practical, functional genomics endpoint against which one may assay putative phamacologic preconditioning agents. Patients undergoing such surgery could receive pharmacological preconditioning to modulate spinal cord ischemic tolerance before the blood supply is cut off, a practical impossibility for people who suffer spinal cord injury. However, evidence from one HSP70 study (Hoehn et al., 2001) suggests that this mediator of preconditioning may also be effective as a treatment after the onset of ischemia. This raises the hope that mediators of ischemic tolerance may also have wider clinical importance for people who suffer spinal ischemia.

of the game, and the neverly of the networklow 19970 tablet percentenent for the protection the second statement of the protection the second statement of the protection of t

Carmel et al.

Microarray Analysis of Spinal Ischemia

Page 28 of 46

Acknowledgements

We thank Jessica Lam, David Kahn and Donna Wilson for outstanding technical support. JBC was a Howard Hughes Medical Student Fellow during the initiation of this project. MM is supported by NS32794. RPH is supported by grants from the New Jersey Commission on Spinal Cord Research and the Spinal Cord Project of the W.M. Keck Center for Collaborative Neuroscience.

Microarray Analysis of Spinal Ischemia

Page 29 of 46

Figure Legends

Figure 1. Graph of microarray results comparing brief ischemic and sham controls. Animals received either brief ischemia (3 or 6 min) or sham operation. The animals were allowed to survive for various times and were sacrificed. RNA was prepared from lumbar spinal cords, reverse transcribed, hybridized to oligonucleotide microarrays, and detected using fluorescent probes. Arrays were scanned, and replicate results (n=4) averaged. Lowess normalized ratios (*Normalized Intensity*; y-axis) of ischemia-treated fluorescence hybridization signal to sham control signal are depicted at various times after ischemia (*Time*; x-axis). Each line represents the ratio of ischemic/sham hybridization for a single probe over time. *All microarray results will be posted to a public web site at the time of publication*. A: 3-min ischemia results. B: 6-min ischemia results. Results were filtered using three criteria: foldchange greater than two, signal intensity approximately two-fold above background, and t-test with a p value less than 0.05. C: Filtered genes from 3-min ischemia experiment (n=5). D: Filtered genes from 6-min ischemia experiment (n=31).

Figure 2. Clustering and validation of 3-min ischemia results. A: Anchor gene clustering. To find genes with similar expression patterns to three genes of interest—hsp70, MT, and egr-1—an "anchor gene" clustering (Carmel et al., 2001) was performed. The 3-min results were filtered at 1.5 fold change to create a subset of 159 genes. The expression patterns for hsp70, MT, and egr-1 were used to find genes with similar patterns using the Standard Correlation metric with values of 0.90 or greater. Each hsp70 probe identified the two other hsp70 probes as close correlates. Likewise, each MT probe was closely correlated to the other two as well as to the small heat shock protein cryab. The expression pattern for egr-1 was correlated with ptpn16, Carmel et al.

Microarray Analysis of Spinal Ischemia

Page 30 of 46

another-IEG. **B: Validation of anchor genes by Q-RT-PCR**. Samples of the same RNA preparation used for microarrays were assayed by Q-RT-PCR. Results (mean ± SEM; n=4) were calculated as fold-change from mean sham to match microarray results.

Figure 3. Clustering and validation of 6-min ischemia results. A: K-means clustering. To partition the 31 genes that passed our filters (see text), we used k-means clustering with k=5. Similarity was measured with the Standard Correlation metric, and clustering was performed iteratively until stable clusters were found. The identity of the genes in each cluster is listed in Table 4. Cluster 1 contains the three probes for hsp70 as well as for heme oxygenase and activating transcription factor 3 (ATF3). Grouped with MT-1 and MT-2 in cluster 3 are the small heat shock proteins cryab and hsp27 among others. Cluster 3 contains BTG2, egr-1, ptpn16, and NGFI-B, all IEGs. Clusters 4 and 5 contain genes that are decreased with ischemia and show inverse patterns. **B: Q-RT-P CR validation of selected genes**. Results are graphed in groups according to k-means clusters. Most induced mRNAs show validation of microarray findings with a greater dynamic range by Q-RT-PCR than microarrays. With the exception of MPZ; none of the decreased genes was validated. Results are mean ± SEM (n=4).

Figure 4. Northern blot results. For Northern blot, spinal cord segments from three animals were pooled in each the 6 min ischemia and sham-operated group. RNA was extracted, electrophoresed, transferred to nitrocellulose membranes, and hybridized with ³²P labeled hsp70 probe (Fig 4A). Lanes A-C represent animals exposed to 6 min ischemia, and lanes D-F are from sham animals. Animals were allowed to survive for various times after ischemia: 4hrs (lanes A and D), 18hrs (lanes B and E), or 24hrs (lanes C and F). Fig. 4B shows quantification of

Microarray Analysis of Spinal Ischemia

Page 31 of 46

Northern blot results expressed as a fold change from sham controls. Results are means \pm SEM. *Significant by Student's t-test at p<0.05.

Typese I, Chartering and within the off-min instantia results. At K-moore electricity To paration de 11 gener that priced one fillers (su tree), we used k-mane electricity with Pe-Similarity wer morecient with the Streader) Constraines metric, and chartering with Pevienne (general cable distance were three). The aterraty of the gener in outh offset in 1996. In Table 4 Cluster I contains the film (cluster in a sector, and is filler from on generation). Table 4 Cluster I contains the film (cluster in legith at and as fill form on generation). Table 4 Cluster I contains the film (cluster in legith at and as fill form on generation). Table 4 Cluster I contains the film (cluster in legith at and as fill form) of generation and share generation throw 0 (ATTO). Cluster is with the first and httl. In cluster 1 we the main heat share parameter throw 0 (ATTO). Cluster is the tree decreased with informing and the metrics of the fill of the fill of the state of the tree decreased with informing and the metrics of the fill of the fill of the state of the tree decreased with informing and the state parameter of the fill of the state of the fill of the state of the

Figure & Harrhorn Mar real-time For Harrhorn Max, apartit and augustatic from time animals were possible in each the 6-min technick and there opticities a point. R143 with article took effective interest, its activation of a simulation of the statistic point. R143 with article took probe (Fig. 6.3), Lanar A-C represent animals engened to 6 and hydroldood with ¹¹9 Tableich hap? anima gained a A.S. Lanar A-C represent animals engened to 6 and hydroldood with ¹¹9 Tableich hap? anima gained b. Animale were about a constitution for vinistra trade offer failured for (Fig. 6.4). Engent A-C represent as entry the for vinistra trade offer failer and the failed for the anima gained b. (Fig. 6.4). Animale were about a constitution of the failer failer and the failer of the failer and 10. (Fig. 6.4) and 10. or 2 days (failer (failer C and F), Fig. 6.4) also are an animalisation of

Carmel et al.

Microarray Analysis of Spinal Ischemia

Page 32 of 46

 Table 1. Oligonucleotide primers for Q-RT-PCR. Primers were designed using PrimerExpress

 software (Applied Biosystems, Inc.) from the same GenBank accession records as the microarray

 probes except for genes that had a NCBI reference sequence for the same UniGene cluster

 (Cryab, Oazi, and Syt7). Gene descriptions are from NCBI.

 Table 2. Relationship of hsp70 microarray probes, Q-RT-PCR primers, and sequence

 identity. Microarrays contain 3 probes for the same protein, HSP70. Q-RT-PCR primers were

 designed for one member of each Unigene cluster.

Table 3. Results after 3 min of spinal cord ischemia by microarray and Q-RT-PCR. Listed is the ratio of ischemic/sham animals at various times after ischemia. mRNAs altered by 2-fold or greater are marked with an asterisk. For Q-RT-PCR results, genes that are significantly different by Student's t-test at p < 0.05 are also marked with an asterisk.

Table 4. Results after 6 min of spinal cord ischemia by microarray and Q-RT-PCR. 31 genes passed the filtering criteria described in the text and are graphed in Fig. 1D. Results are presented as a ratio of ischemia/sham. Genes are grouped according to their k-means clusters as depicted in Fig. 3A. For microarray results, all genes show significant change from sham controls (p < 0.05 by t-test) at one time point or more. mRNAs altered by 2-fold or greater are marked with an asterisk. For Q-RT-PCR results, genes that are significantly different by Student's t-test at p < 0.05 are marked with an asterisk.

Microarray Analysis of Spinal Ischemia

Page 33 of 46

- -

Reference List

Abe,K., Kawagoe,J., Sato,S., Sahara,M., Kogure,K. 1991. Induction of the 'zinc finger' gene after transient focal ischemia in rat cerebral cortex. Neurosci Lett 123, 248-50.

Akbar, M.T., Lundberg, A.M., Liu, K., Vidyadaran, S., Wells, K.E., Dolatshad, H., Wynn, S., Wells, D.J., Latchman, D.S., De Belleroche, J.S. 2003. The neuroprotective effects of heat shock protein 27 overexpression in transgenic animals against kainate-induced seizures and hippocampal cell death. J Biol Chem.

Akbar,M.T., Wells,D.J., Latchman,D.S., de Belleroche,J. 2001. Heat shock protein 27 shows a distinctive widespread spatial and temporal pattern of induction in CNS glial and neuronal cells compared to heat shock protein 70 and caspase 3 following kainate administration. Brain Res Mol Brain Res 93, 148-63.

Alessi, D.R., Smythe, C., Keyse, S.M. 1993. The human CL100 gene encodes a Tyr/Thr-protein phosphatase which potently and specifically inactivates MAP kinase and suppresses its activation by oncogenic ras in Xenopus oocyte extracts. Oncogene 8, 2015-20.

Allen-Jennings, A.E., Hartman, M.G., Kociba, G.J., Hai, T. 2001. The roles of ATF3 in glucose homeostasis. A transgenic mouse model with liver dysfunction and defects in endocrine pancreas. J Biol Chem 276, 29507-14.

Arrigo, A.P., Welch, W.J. 1987. Characterization and purification of the small 28,000-dalton mammalian heat shock protein. J Biol Chem 262, 15359-69.

Bai,G., Kusiak,J.W. 1995. Functional analysis of the proximal 5'-flanking region of the N-methyl-D-aspartate receptor subunit gene, NMDAR1. J Biol Chem 270, 7737-44.

Barone, F.C., White, R.F., Spera, P.A., Ellison, J., Currie, R.W., Wang, X., Feuerstein, G.Z. 1998. Ischemic preconditioning and brain tolerance: temporal histological and functional outcomes, protein synthesis requirement, and interleukin-1 receptor antagonist and early gene expression. Stroke 29, 1937-50.

Beckmann, A.M., Davidson, M.S., Goodenough, S., Wilce, P.A. 1997. Differential expression of Egr-1-like DNAbinding activities in the naive rat brain and after excitatory stimulation. J Neurochem 69, 2227-37.

Beckmann, A.M., Wilce, P.A. 1997. Egr transcription factors in the nervous system. Neurochem Int 31, 477-510.

Bernaudin, M., Tang, Y., Reilly, M., Petit, E., Sharp, F.R. 2002. Brain genomic response following hypoxia and reoxygenation in the neonatal rat. Identification of genes that might contribute to hypoxia-induced ischemic tolerance. J Biol Chem 277, 39728-38.

Boschert, U., Dickinson, R., Muda, M., Camps, M., Arkinstall, S. 1998. Regulated expression of dual specificity protein phosphatases in rat brain. Neuroreport 9, 4081-6.

Bradbury, A., Possenti, R., Shooter, E.M., Tirone, F. 1991. Molecular cloning of PC3, a putatively secreted protein whose mRNA is induced by nerve growth factor and depolarization. Proc Natl Acad Sci U S A 88, 3353-7.

Cai,L., Cherian,M.G., Iskander,S., Leblanc,M., Hammond,R.R. 2000. Metallothionein induction in human CNS in vitro: neuroprotection from ionizing radiation. Int J Radiat Biol 76, 1009-17.

Camps, M., Nichols, A., Arkinstall, S. 2000. Dual specificity phosphatases: a gene family for control of MAP kinase function. Faseb J 14, 6-16.

Carmel et al.

Microarray Analysis of Spinal Ischemia

Page 34 of 46

Carmel,J.B., Galante,A., Soteropolios,P., Tolias,P., Recce,M., Young,W., Hart,R.P. 2001. Gene expression profiling of acute spinal cord injury reveals spreading inflammatory signals and neuron loss. Physiol Genomics 7, 201-13.

Castro-Moure, F., Kupsky, W., Goshgarian, H.G. 1997. Pathophysiological classification of human spinal cord ischemia. J Spinal Cord Med 20, 74-87.

Chan, P.H. 1996. Role of oxidants in ischemic brain damage. Stroke 27, 1124-9.

Chan,R.K., Brown,E.R., Ericsson,A., Kovacs,K.J., Sawchenko,P.E. 1993. A comparison of two immediate-early genes, c-fos and NGFI-B, as markers for functional activation in stress-related neuroendocrine circuitry. J Neurosci 13, 5126-38.

Chen, B.P., Liang, G., Whelan, J., Hai, T. 1994. ATF3 and ATF3 delta Zip. Transcriptional repression versus activation by alternatively spliced isoforms. J Biol Chem 269, 15819-26.

Chen,B.P., Wolfgang,C.D., Hai,T 1996. Analysis of ATF3, a transcription factor induced by physiological stresses and modulated by gadd153/Chop10. Mol Cell Biol 16, 1157-68.

Chen,K., Zhang,J., Ye,C. 1997. [Metallothionein involvement in the delayed protection after ischemic or anoxic preconditioning in myocardium on cultured cardiomyocytes]. Zhonghua Yi Xue Za Zhi 77, 106-10.

Chihab, R., Ferry, C., Koziel, V., Mpnin, P., Daval, J.L. 1998. Sequential activation of activator protein-1-related transcription factors and JNK protein kinases may contribute to apoptotic death induced by transient hypoxia in developing brain neurons. Brain Res Mol Brain Res 63, 105-20.

Chu,H.M., Tan,Y., Kobierski,L.A., Balsam,L.B., Comb,M.J. 1994. Activating transcription factor-3 stimulates 3',5'cyclic adenosine monophosphate-dependent gene expression. Mol Endocrinol 8, 59-68.

Collaco-Moraes, Y., Aspey, B.S., De Belleroche, J.S., Harrison, M.J. 1994. Focal ischemia causes an extensive induction of immediate early genes that are sensitive to MK-801. Stroke 25, 1855-60.

Cox,G.S., O'Hara,P.J., Hertzer,N.R., Piedmonte,M.R., Krajewski,L.P., Beven,E.G. 1992. Thoracoabdominal aneurysm repair: a representative experience. J Vasc Surg 15, 780-7.

Cui,M.Z., Parry,G.C., Oeth,P., Latson,H., Smith,M., Huang,R.P., Adamson,E.D., Mackman,N. 1996. Transcriptional regulation of the tissue factor gene in human epithelial cells is mediated by Sp1 and EGR-1. J Biol Chem 271, 2731-9.

Dillmann, W.H. 1999. Small heat shock proteins and protection against injury. Ann N Y Acad Sci 874, 66-8.

Ducker, T.B., Bellegarrigue, R., Salcman, M., Walleck, C. 1984. Timing of operative care in cervical spinal cord injury. Spine 9, 525-531.

Ebadi, M., Iversen, P.L., Hao, R., Cerutis, D.R., Rojas, P., Happe, H.K., Murrin, L.C., Pfeiffer, R.F. 1995. Expression and regulation of brain metallothionein. Neurochem Int 27, 1-22.

el-Ghissassi, F., Valsesia-Wittmanh, S., Falette, N., Duriez, C., Walden, P.D., Puisieux, A. 2002. BTG2(TIS21/PC3) induces neuronal differentiation and prevents apoptosis of terminally differentiated PC12 cells. Oncogene 21, 6772-78.

Emerson, M.R., Samson, F.E., Pazdernik, T.L. 2000. Effects of hypoxia preconditioning on expression of metallothionein-1,2 and heme oxygenase-1 before and after kainic acid-induced seizures. Cell Mol Biol (Noisy-legrand) 46, 619-26.

Page 35 of 46

Gerlai, R., Thibodeaux, H., Palmer, J.T., van Lookeren Campagne, M., Van Bruggen, N. 2000. Transient focal cerebral ischemia induces sensorimotor deficits in mice. Behav Brain Res 108, 63-71.

Gubits, R.M., Burke, R.E., Casey-McIntosh, G., Bandele, A., Munell, F. 1993. Immediate early gene induction after neonatal hypoxia-ischemia. Brain Res Mol Brain Res 18, 228-38.

Hai,T., Curran,T. 1991. Cross-family dimerization of transcription factors Fos/Jun and ATF/CREB alters DNA binding specificity. Proc Natl Acad Sci U S A 88, 3720-4.

Hai,T., Wolfgang,C.D., Marsee,D.K., Allen,A.E., Sivaprasad,U. 1999. ATF3 and stress responses. Gene Expr 7, 321-35.

Hamer, D.H. 1986. Metallothionein. Annu Rev Biochem 55, 913-51.

Hazel, T.G., Nathans, D., Lau, L.F. 1988. A gene inducible by serum growth factors encodes a member of the steroid and thyroid hormone receptor superfamily. Proc Natl Acad Sci U S A 85, 8444-8.

Herdegen, T., Brecht, S., Mayer, B., Leah, J., Kummer, W., Bravo, R., Zimmermann, M. 1993. Long-lasting expression of JUN and KROX transcription factors and nitric oxide synthase in intrinsic neurons of the rat brain following axotomy. J Neurosci 13, 4130-45.

Hoehn,B., Ringer,T.M., Xu,L., Giffard,R.G., Sapolsky,R.M., Steinberg,G.K., Yenari,M.A. 2001. Overexpression of HSP72 after induction of experimental stroke protects neurons from ischemic damage. J Cereb Blood Flow Metab 21, 1303-9.

Honkaniemi, J., Sagar, S.M., Pyykonen, I., Hicks, K.J., Sharp, F.R. 1995. Focal brain injury induces multiple immediate early genes encoding zinc finger transcription factors. Brain Res Mol Brain Res 28, 157-63.

Honkaniemi, J., Sharp, F.R. 1996. Global ischemia induces immediate-early genes encoding zinc finger transcription factors. J Cereb Blood Flow Metab 16, 557-65.

Honkaniemi, J., States, B.A., Weinstein, P.R., Espinoza, J., Sharp, F.R. 1997. Expression of zinc finger immediate early genes in rat brain after permanent middle cerebral artery occlusion. J Cereb Blood Flow Metab 17, 636-46.

Hughes, T.R., Mao, M., Jones, A.R., Burchard, J., Marton, M.J., Shannon, K.W., Lefkowitz, S.M., Ziman, M., Schelter, J.M., Meyer, M.R., Kobayashi, S., Davis, C., Dai, H., He, Y.D., Stephaniants, S.B., Cavet, G., Walker, W.L., West, A., Coffey, E., Shoemaker, D.D., Stoughton, R., Blanchard, A.P., Friend, S.H., Linsley, P.S. 2001. Expression profiling using microarrays fabricated by an ink-jet oligonucleotide synthesizer. Nat. Biotechnol. 19, 342-347.

Iacopeti, P., Michelini, M., Stuckmann, I., Oback, B., Aaku-Saraste, E., Huttner, W. B. 1999. Expression of the antiproliferative gene TIS21 at the onset of neurogenesis identifies single neuroepithelial cells that switch from proliferative to neuron-generating division. Proc Natl Acad Sci U S A 96, 4639-44.

Irving,E.A., Bamford,M. 2002. Role of mitogen- and stress-activated kinases in ischemic injury. J Cereb Blood Flow Metab 22, 631-47.

Iszard, M.B., Liu, J., Liu, Y., Dalton, T., Andrews, G.K., Palmiter, R.D., Klaassen, C.D. 1995. Characterization of metallothionein-I-transgenic mice. Toxicol Appl Pharmacol 133, 305-12.

Iwaki, T., Kume-Iwaki, A., Goldman, J.E. 1990. Cellular distribution of alpha B-crystallin in non-lenticular tissues. J Histochem 38, 31-9.

Jin, K., Mao, X.O., Eshoo, M.W., Nagayama, T., Minami, M., Simon, R.P., Greenberg, D.A. 2001. Microarray analysis of hippocampal gene expression in global cerebral ischemia. Ann Neurol 50, 93-103.

Carmel et al.

Microarray Analysis of Spinal Ischemia

Page 36 of 46

Johansson, I.M., Wester, P., Hakova, M., Gu, W., Seckl, J.R., Olsson, T. 2000. Early and delayed induction of immediate early gene expression in a novel focal cerebral ischemia model in the rat. Eur J Neurosci 12, 3615-25.

Kelly, S., Bieneman, A., Horsburgh, K., Hughes, D., Sofroniew, M.V., McCulloch, J., Uney, J.B. 2001. Targeting expression of hsp70i to discrete neuronal populations using the Lmo-1 promoter: assessment of the neuroprotective effects of hsp70i in vivo and in vitro. J Cereb Blood Flow Metab 21, 972-81.

Keyse,S.M., Emslie,E.A. 1992. Oxidative stress and heat shock induce a human gene encoding a protein-tyrosine phosphatase. Nature 359, 644-7.

Khachigian,L.M., Lindner,V., Williams,A.J., Collins,T. 1996. Egr-1-induced endothelial gene expression: a common theme in vascular injury. Science 271, 1427-31.

Kramer, B., Meichle, A., Hensel, G., Charnay, P., Kronke, M. 1994. Characterization of an Krox-24/Egr-1-responsive element in the human tumor necrosis factor promoter. Biochim Biophys Acta 1219, 413-21.

Lanteri-Minet, M., de Pommery, J., Herdegen, T., Weil-Fugazza, J., Bravo, R., Menetrey, D. 1993. Differential time course and spatial expression of Føs, Jun, and Krox-24 proteins in spinal cord of rats undergoing subacute or chronic somatic inflammation. J Comp Neurol 333, 223-35.

Lewis,S.E., Mannion,R.J., White,F.A., Coggeshall,R.E., Beggs,S., Costigan,M., Martin,J.L., Dillmann,W.H., Woolf,C.J. 1999. A role for HSP27 in sensory neuron survival. J Neurosci 19, 8945-53.

Lin, T.N., Chen, J.J., Wang, S.J., Cheng, J.T., Chi, S.I., Shyu, A.B., Sun, G.Y., Hsu, C.Y. 1996. Expression of NGFI-B mRNA in a rat focal cerebral ischemia-reperfusion model. Brain Res Mol Brain Res 43, 149-56.

Liu, J., Kershaw, W.C., Klaassen, C.D. 1991. The protective effect of metallothionein on the toxicity of various metals in rat primary hepatocyte culture. Foxicol Appl Pharmacol 107, 27-34.

Majda, B.T., Meloni, B.P., Rixon, N., Knuckey, N.W. 2001. Suppression subtraction hybridization and northern analysis reveal upregulation of heat shock, trkB, and sodium calcium exchanger genes following global cerebral ischemia in the rat. Brain Res Mol Brain Res 93, 173-9.

Maroney,A.C., Finn,J.P., Bozyczło-Coyne,D., O'Kane,T.M., Neff,N.T., Tolkovsky,A.M., Park,D.S., Yan,C.Y., Troy,C.M., Greene,L.A. 1999. CEP-1347 (KT7515), an inhibitor of JNK activation, rescues sympathetic neurons and neuronally differentiated PC1P cells from death evoked by three distinct insults. J Neurochem 73, 1901-12.

Martin, J.L., Bluhm, W.F., He,H., Mestril, R., Dillmann, W.H. 2002. Mutation of COOH-terminal lysines in overexpressed alpha B-crystallin abrogates ischemic protection in cardiomyocytes. Am J Physiol Heart Circ Physiol 283, 85-91.

Martin, J.L., Hickey, E., Weber, L.A., Dillmann, W.H., Mestril, R. 1999. Influence of phosphorylation and oligomerization on the protective role of the small heat shock protein 27 in rat adult cardiomyocytes. Gene Expr 7, 349-55.

Martin, J.L., Mestril, R., Hilal-Dandan, R., Brunton, L.L., Dillmann, W.H. 1997. Small heat shock proteins and protection against ischemic injury in cardiac myocytes. Circulation 96, 4343-8.

Matsumoto,M., Ohtake,K., Wakamatsu,H., Oka,S., Kiyoshima,T., Nakakimura,K., Sakabe,T. 2001. The time course of acquisition of ischemic tolerance and induction of heat shock protein 70 after a brief period of ischemia in the spinal cord in rabbits. Anesth Andlg 92, 418-23.

Matsuyama,K., Chiba,Y., Ihaya,A., Kimura,T., Tanigawa,N., Muraoka,R. 1997. Effect of spinal cord preconditioning on paraplegia during cross-clamping of the thoracic aorta. Ann Thorac Surg 63, 1315-20.

Page 37 of 46

Matsuyama,N., Leavens,J.E., McKinnon,D., Gaudette,G.R., Aksehirli,T.O., Krukenkamp,I.B. 2000. Ischemic but not pharmacological preconditioning requires protein synthesis. Circulation 102, 312-8.

Mautes, A.E., Weinzierl, M.R., Donovan, F., Noble, L.J. 2000. Vascular events after spinal cord injury: contribution to secondary pathogenesis. Phys Ther 80, 673-87.

Mestril, R., Dillmann, W.H. 1995. Heat shock proteins and protection against myocardial ischemia. J Mol Cell Cardiol 27, 45-52.

Milbrandt, J. 1988. Nerve growth factor induces a gene homologous to the glucocorticoid receptor gene. Neuron 1, 183-8.

Motoyoshi,N., Sakurai,M., Hayashi,T., Aoki,M., Abe,K., Itoyama,Y., Tabayashi,K. 2001. Establishment of a local cooling model against spinal cord ischemia representing prolonged induction of heat shock protein. J Thorac Cardiovasc Surg 122, 351-7.

Nakata, N., Kato, H., Kogure, K. 1993. Inhibition of ischaemic tolerance in the gerbil hippocampus by quercetin and anti-heat shock protein-70 antibody. Neuroreport 4, 695-8.

Nesic, O., Svrakic, N.M., Xu, G.Y., McAdoo, D., Westlund, K.N., Hulsebosch, C.E., Ye, Z., Galante, A., Soteropoulos, P., Tolias, P., Young, W., Hart, R.P., Perez-Piol.J.R. 2002. DNA microarray analysis of the contused spinal cord: Effect of NMDA receptor inhibition. J Neurosci Res 68, 406-23.

Neumann-Haefelin, T., Wiessner, C., Vogel, P., Back, T., Hossmann, K.A. 1994. Differential expression of the immediate early genes c-fos, c-jun, junB, and NGFI-B in the rat brain following transient forebrain ischemia. J Cereb Blood Flow Metab 14, 206-16.

Nowak, T.S., Jr., Ikeda, J., Nakajima, T. 1990. 70-kDa heat shock protein and c-fos gene expression after transient ischemia. Stroke 21, 107-11.

Okamoto, Y., Chaves, A., Chen, J., Kelley, R., Jones, K., Weed, H.G., Gardner, K.L., Gangi, L., Yamaguchi, M., Klomkleaw, W., Nakayama, T., Hamlin, R.L., Carnes, C., Altschuld, R., Bauer, J., Hai, T. 2001. Transgenic mice with cardiac-specific expression of activating transcription factor 3, a stress-inducible gene, have conduction abnormalities and contractile dysfunction. Am J Pathol 159, 639-50.

Omata, N., Murata, T., Takamatsu, S., Maruoka, N., Wada, Y., Yonekura, Y., Fujibayashi, Y. 2002. Hypoxic tolerance induction in rat brain slices following hypoxic preconditioning due to expression of neuroprotective proteins as revealed by dynamic changes in glucose metabolism. Neurosci Lett 329, 205-8.

Onody, A., Zvara, A., Hackler, L., Jr., Vigh, L., Ferdinandy, P., Puskas, L.G. 2003. Effect of classic preconditioning on the gene expression pattern of rat hearts: a DNA microarray study. FEBS Lett 536, 35-40.

Palmiter, R.D. 1998. The elusive function of metallothioneins. Proc Natl Acad Sci U S A 95, 8428-30.

Perdrizet, G.A., Lena, C.J., Shapiro, D.S., Rewinski, M.J. 2002. Preoperative stress conditioning prevents paralysis after experimental aortic surgery: increased heat shock protein content is associated with ischemic tolerance of the spinal cord. J. Thorac Cardiovasc Surg 124, 162-70.

Puissant, C., Houdebine, L.M. 1990. An improvement of the single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Biotechniques 8, 148-9.

Rajeevan, M.S., Vernon, S.D., Taysavang, N., Unger, E.R. 2001. Validation of array-based gene expression profiles by real-time (kinetic) RT-PCR. J Mol Diagn 3, 26-31.

Microarray Analysis of Spinal Ischemia

Page 38 of 46

Ririe,K.M., Rasmussen,R.P., Wittwer,C.T. 1997. Product differentiation by analysis of DNA melting curves during the polymerase chain reaction. Anal Biochem 245, 154-60.

Rouault, J.P., Falette, N., Guehenneux, F., Guillot, C., Rimokh, R., Wang, Q., Berthet, C., Moyret-Lalle, C., Savatier, P., Pain, B., Shaw, P., Berger, R., Samarut, J., Magaud, J.P., Ozturk, M., Samarut, C., Puisieux, A. 1996. Identification of BTG2, an antiproliferative p53-dependent component of the DNA damage cellular response pathway. Nat Genet 14, 482-6.

Rybnikova, E., Tulkova, E., Pelto-Huikko, M., Samoilov, M. 2002. Mild preconditioning hypoxia modifies nerve growth factor-induced gene A messenger RNA expression in the rat brain induced by severe hypoxia. Neurosci Lett 329, 49-52.

Saal,L.H., Troein,C., Vallon-Christersson,J., Gruvberger,S., Borg,A., Peterson,C. 2002. BioArray Software Environment (BASE): a platform for comprehensive management and analysis of microarray data. Genome Biol 3, SOFTWARE5003.

Satoh, M., Naganuma, A., Imura, N. 1988. Metallothionein induction prevents toxic side effects of cisplatin and adriamycin used in combination. Cancer Chemother Pharmacol 21, 176-8.

Sharp,F.R., Kinouchi,H., Koistinaho,J., Chan,P.H., Sagar,S.M. 1993. HSP70 heat shock gene regulation during ischemia. Stroke 24, 72-5.

Shingu,T., Bornstein,P. 1994. Overlapping Egr-1 and Sp1 sites function in the regulation of transcription of the mouse thrombospondin 1 gene. J Biol Chem 269, 32551-7.

Shohami,E., Jacobs,T.P., Hallenbeck,J.M., Feuerstein,G. 1987. Increased thromboxane A2 and 5-HETE production following spinal cord ischemia in the rabbit. Prostaglandins Leukot Med 28, 169-81.

Soriano, M.A., Tessier, M., Certa, U., Gill, R. 2000. Parallel gene expression monitoring using oligonucleotide probe arrays of multiple transcripts with an animal model of focal ischemia. J Cereb Blood Flow Metab 20, 1045-55.

Stears, R. L., Getts, R. C., Gullans, S. R. 2000. A novel, sensitive detection system for high-density microarrays using dendrimer technology. Physiol Genomics 3, 93-99.

Strohm, C., Barancik, M., von Bruehl, M., Stmiskova, M., Ullmann, C., Zimmermann, R., Schaper, W. 2002. Transcription inhibitor actinomycln-D abolishes the cardioprotective effect of ischemic reconditioning. Cardiovasc Res 55, 602-18.

Sun, H., Charles, C.H., Lau, L.F., Tonks, N.K. 1993. MKP-1 (3CH134), an immediate early gene product, is a dual specificity phosphatase that dephdsphorylates MAP kinase in vivo. Cell 75, 487-93.

Taira, Y., Marsala, M. 1996. Effect of proximal arterial perfusion pressure on function, spinal cord blood flow, and histopathologic changes after increasing intervals of aortic occlusion in the rat. Stroke 27, 1850-8.

Tator, C.H., Fehlings, M.G. 1991. Review of the secondary injury theory of acute spinal cord trauma with emphasis on vascular mechanisms. J Neurosurg 75, 15-26.

Tomasovic, S.P., Sinha, A., Steck, P.A. 1985. Heat transient related changes in stress-protein synthesis. Radiat Res 102, 336-46.

Trendelenburg,G., Prass,K., Priller,J., Kapinya,K., Polley,A., Muselmann,C., Ruscher,K., Kannbley,U., Schmitt,A.O., Castell,S., Wiegand, F., Meisel,A., Rosenthal,A., Dirmagl,U. 2002. Serial analysis of gene expression identifies metallothionein-II as major neuroprotective gene in mouse focal cerebral ischemia. J Neurosci 22, 5879-88.

Page 39 of 46

Truettner, J., Busto, R., Zhao, W., Ginsberg, M.D., Perez-Pinzon, M.A. 2002. Effect of ischemic preconditioning on the expression of putative neuroprotective genes in the rat brain. Brain Res Mol Brain Res 103, 106-15.

Tsujino,H., Kondo,E., Fukuoka,T., Dai,Y., Tokunaga,A., Miki,K., Yonenobu,K., Ochi,T., Noguchi,K. 2000. Activating transcription factor 3 (ATF3) induction by axotomy in sensory and motoneurons: A novel neuronal marker of nerve injury. Mol Cell Neurosci 15, 170-82.

van Lookeren Campagne, M., Thibodeaux, H., Van Bruggen, N., Caims, B., Gerlai, R., Palmer, J.T., Williams, S.P., Lowe, D.G. 1999. Evidence for a protective role of metallothionein-1 in focal cerebral ischemia. Proc Natl Acad Sci US A 96, 12870-5.

Verdant,A., Cossette,R., Page,A., Baillot,R., Dontigny,L., Page,P. 1995. Aneurysms of the descending thoracic aorta: three hundred sixty-six consecutive cases resected without paraplegia. J Vasc Surg 21, 385-90.

Wagstaff,M.J., Collaco-Moraes,Y., Smith,J., De Belleroche,J.S., Coffin,R.S., Latchman,D.S. 1999. Protection of neuronal cells from apoptosis by Hsp27 delivered with a herpes simplex virus-based vector. J Biol Chem 274, 5061-9.

Wang,G.W., Zhou,Z., Klein,J.B., Kang,Y.J. 2001. Inhibition of hypoxia/reoxygenation-induced apoptosis in metallothionein-overexpressing cardiomyocytes. Am J Physiol Heart Circ Physiol 280, 2292-9.

Wang,H.Y., Malek,R.L., Kwitek,A.E., Greene,A.S., Luu,T.V., Behbahani,B., Frank,B., Quackenbush,J., Lee,N.H. 2003. Assessing unmodified 70-mer oligonucleotide probe performance on glass-slide microarrays. Genome Biol. 4, R5.

Watson, M.A., Milbrandt, J. 1989. The NGFI-B gene, a transcriptionally inducible member of the steroid receptor gene superfamily: genomic structure and expression in rat brain after seizure induction. Mol Cell Biol 9, 4213-9.

Wiessner, C., Neumann-Haefelin, T., Vogel, P., Back, T., Hossmann, K.A. 1995. Transient forebrain ischemia induces an immediate-early gene encoding the mitogen-activated protein kinase phosphatase 3CH134 in the adult rat brain. Neuroscience 64, 959-66.

Williams, G.T., Lau, L.F. 1993. Activation of the inducible orphan receptor gene nur77 by serum growth factors: dissociation of immediate-early and delayed-early responses. Mol Cell Biol 13, 6124-36.

Wilson, T.E., Fahrner, T.J., Johnston, M., Milbrandt, J. 1991. Identification of the DNA binding site for NGFI-B by genetic selection in yeast. Science 252, 1296-300.

Wilson, T.E., Mouw, A.R., Weaver, C.A., Milbrandt, J., Parker, K.L. 1993. The orphan nuclear receptor NGFI-B regulates expression of the gene encoding steroid 21-hydroxylase. Mol Cell Biol 13, 861-8.

Wisden, W., Errington, M.L., Williams, S., Dunnett, S.B., Waters, C., Hitchcock, D., Evan, G., Bliss, T.V., Hunt, S.P. 1990. Differential expression of immediate early genes in the hippocampus and spinal cord. Neuron 4, 603-14.

Wittwer, C.T., Herrmann, M.G., Moss, A.A., Rasmussen, R.P. 1997. Continuous fluorescence monitoring of rapid cycle DNA amplification. Biotechniques 22, 130-1.

Worley, P.F., Christy, B.A., Nakabeppu, Y., Bhat, R.V., Cole, A.J., Baraban, J.M. 1991. Constitutive expression of zif268 in neocortex is regulated by synaptic activity. Proc Natl Acad Sci U S A 88, 5106-10.

Yang,L.C., Orendacova,J., Wang,V., Ishikawa,T., Yaksh,T.L., Marsala,M. 2000. Transient spinal cord ischemia in rat: the time course of spinal FOS protein expression and the effect of intraischemic hypothermia (27 degrees C). Cell Mol Neurobiol 20, 351-65.

Carmel et al.

Microarray Analysis of Spinal Ischemia

Page 40 of 46

Yang,Y.H., Dudoit,S., Luu,P., Lin,D.M., Peng,V., Ngai,J., Speed,T.P. 2002. Normalization for cDNA microarray data: arobust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res 30, e15.

Yang, Y.H., Speed, T. 2002. Design issues for cDNA microarray experiments. Nat Rev Genet 3, 579-88.

Yin,T., Sandhu,G., Wolfgang,C.D., Burrier,A., Webb,R.L., Rigel,D.F., Hai,T., Whelan,J. 1997. Tissue-specific pattern of stress kinase activation in ischemic/reperfused heart and kidney. J Biol Chem 272, 19943-50.

Yoon, J.K., Lau, L.F. 1993. Transcriptional activation of the inducible nuclear receptor gene nur77 by nerve growth factor and membrane depolarization in PC12 cells. J Biol Chem 268, 9148-55.

Zhang, P., Abraham, V.S., Kraft, K. R., Rabchevsky, A.G., Scheff, S.W., Swain, J.A. 2000. Hyperthermic preconditioning protects against spinal cord ischemic injury. Ann Thorac Surg 70, 1490-5.

....

-

Table 1.

Gene	Description	GenBank	Forward	Reverse
ATF3	activation transcription factor 3	NM 012912	CGCCATCCAGAACAAGCAC	GACTCCAGCGCAGAGGACAT
Cryab	alpha B crystallin	NM 012935	CGAACATGGCTTCATCTCCA	GCTGGGATCCGGTACTTCCT
Egr-1	early growth response 1	NM 012551	CAGCAGCGCTTTCAATCCTC	TGCTCGTAGGGTGM2TTCGC
Fos	fos	<u>X06769</u>	CTTCTCAATGACCCTGAGCCC	AATGTTCTGM2ACCGGCTCCA
GlyRA1	glycine receptor A1	NM 013133	GATGCCAGGATCAGACCCAA	GCAACTCACGTTCACAGGAGG
HemeOX	heme oxygenase	NM 012580	AGAGCGAAACAAGCAGAACCC	TCCTCAGGGAAGTAGAGCGG
Hsp27	heat shock protein 27	NM 031970	TGCCCAAAGCAGTCACACAA	CGAAAGTGACCGGAATGGTG
Hsp70.1	heat shock protein 70.1	NM 031971	TTCAATATGAAGAGCGCCGTG	GCTGATCTGM2CCCTGM2AGACC
Hsp70.2	heat shock protein 70.2	Z75029	AGAGGCTCTTTCTGGCGCTC	GGCCACCCATCTGTCTCCTAG
Nfkbia	NF kappa B inhibitor, alpha	X63594	AGGCACTTCTGAAAGCTGGC	TTCCTCGAAAGTCTCGGAGC
MPZ	myelin protein zero	NM 017027	CCCCAGTAGAACCAGCCTCA	TCCAGGCCCATCATGTTCTT
MRG-3	memory-related gene	U95149	ACATGACAGGACAGCATGGC	CATGM2GTCTGCACACCTCTTTTT
MT-1	Metallothionein 1	J00750	CTGCTCCAAATGTGCCCAG	CACTGM2TCCGAGGCACCTTT
MT-2	Metallothionein 2	M11794	TGCAAGAAAAGCTGCTGTTCC	GGAGCACTTCGCACAGCC
MT-3	Metallothionein 3	NM 053968	TGAGACCTGCCCCTGTCCTA	CATTGM2TCCGAGCAGGTGC
Oazi	ornithine decarboxylase antizyme inhibitor	NM 022585	AATTCCGCCGAAAAAGAGAAG	GATAACGGCCCAAAGAGTCG
Syn7	synaptotagmin 7	NM 021659	TCTGTCTCGGACCTCGTCAAC	GGAGAGCATGAGCATCTCGC
Ttpa	tocopherol transfer protein alpha	NM 013048	GCGTTATTCCCATGACCCG	CCAAAGACTTGM2GTTTCCCG
UVB	ultraviolet B radiation-activated gene	U12526	GGACAACTGAGTAGGACTTCGGG	TAGCGGGCCTTAGAGGTGAC

Table 2.

.

Probe	GenBank Accession	Unigene Cluster	Q-RT-PCR Forward Primer	Q-RT-PCR Reverse Primer		
Heat shock protein 70	L16764	Rn.1950	5'-TTCAATATGAAGAGCGCCGTG-3'	5'-GCTGATCTGM2CCCTGM2AGACC-3		
Heat shock 70kD protein 1A	NM 031971					
Hsp70.2 mRNA for heat shock protein 70	Z75029	Rn.81083	5'-AGAGGCTCTTTCTGGCGCTC-3'	5'-GGCCACCCATCTGTCTCCTAG-3'		

Table 3.

GenBank	Description	Abbrev	Microarray			Q-RT-PCR				
Cluster 1		19 A.	0.5	6	12	24	0.5	6	12	24
L16764	Heat shock protein 70-1	Hspala	5.46*	1.88	1.33	0.89	26.68*	10.99*	11.08	0.84
Z75029	Hsp70.2 mRNA for heat shock protein 70	Hsp70.2	4.87*	3.05*	2.50*	1.01	26.34*	11.75*	13.60	0.91
NM 031971	Heat shock protein 70-1	Hspala	3.43*	1.49	1.23	0.84				
Cluster 2						all and				
M11794	Metallothionein-2 and metallothionein-1 genes	Mtla	0.81	2.08*	1.88	0.76	0.39*	3.42*	2.47*	1.11
J00750	Metallothionein 1	Mt1	0.93	4.44*	3.67*	0.71	0.79	5.72*	4.01*	1.20
M55534	Crystallin, alpha B	Сгуар	0.85	1.64	1.79	1.04	0.79	2.15*	2.25*	1.12
<u>M11794</u>	Metallothionein-2 and metallothionein-1 genes	Mtla	0.98	1.92	1.57	1.08	- Carro	Sec. 1	Sector Sector	
Cluster 3	and the second	and the second	a de la come				1			
NM 012551	Early growth response 1 (Egr1)	Egr-1	1.91	0.77	0.79	0.76	2.31*	0.39*	0.29*	0.32*
U02553	Protein tyrosine phosphatase, non-recentor type 16	Pton16	1.60	0.63	0.59	0.65	1.0500	SPULLUI	7147.1.8	18.05

Table 4

Cluster 1 Description 0.5 6 12 24 L16764 Heat shock protein 70-1 Hspala 13.98* 10.83* 16.25* 1.98 24.89* 83.48* 96.93* 6.70* Z75022 HSp70.2 mRNA. for heat shock protein 70-1 Hsp7al 10.79* 10.81* 17.96* 1.55 8.78* 10.01* 83.48* 96.93* 6.70* NM 012912 Activating transcription factor 3 Arf3 2.18* 1.47 1.37 10.01 8.77* 5.20 4.26* 0.78 5.20 4.26* 0.78 NM 012580 Heme oxygenase Hmoxi 1.48 1.98 2.40* 1.11 1.78 1.56* 6.78 2.83 M11794 Rat metallothionein-2 and metallothionein-1 genes Mt1a 0.99 4.38* 3.69* 1.61 1.44 1.31 1.64* 3.10 1.98* 3.38* M55534 Cryatalin, alpha B Cryab 0.83 1.48 2.31* 1.21 1.30 3.35 2.30*	Genbank		Abbrev	Microarray				Q-RT-PCR				
L16764 Heat shock protein 70-1 Hspala 19.38* 10.33* 16.25* 19.8 24.89* 33.48* 96.93* 6.70* Z75022 Hsp70.2 mRNA for heat shock protein 70-1 Hspala 7.20* 6.42* 11.69* 1.52* 27.52* 80.88* 101.01* 10.92* NM 012912 Activating transcription factor 3 ArB 2.18* 1.47 1.37 101 X89968 NSF protein attachment protein alpha Napa 2.03* 1.08 1.20* 1.70* 1.21* 1.78* 5.20 4.26* 0.78 M11294 Rat metallothionein-2 and metallothionein-1 genes Mt1a 1.02 5.41* 5.02* 1.71 1.78 1.58 1.61* 1.15 M11794 Rat metallothionein 1 Mt1 1.06 6.05* 4.89* 1.61* 3.10 1.98* 3.38* 1.64* 3.10 1.98* 3.38* 1.64* 3.10 1.64* 3.10 1.98* 3.38* 1.64* 3.10 1.98* 3.38* 1.64* 3.10 1.98* 3.38* 1.64* 3.10 1.98* 3.38* <th>Cluster 1</th> <th>Description</th> <th></th> <th>0.5</th> <th>6</th> <th>12</th> <th>24</th> <th>0.5</th> <th>6</th> <th>12</th> <th>24</th>	Cluster 1	Description		0.5	6	12	24	0.5	6	12	24	
ZZ7502 Hsp70.2 10.79* 10.81* 17.96* 2.76* 27.52* 80.88* 101.01* 10.92* NM 031271 Heat shock protein 70-1 Hsp01.7 7.20* 6.42* 11.69* 1.55 NM 012212 Activating transcription factor 3 Act3 2.18* 1.44 1.37 1.01 X89968 NSF protein attachment protein alpha Napa 2.03* 1.08 1.20 1.90 NM 012212 Activating transcription factor 3 Mtla 0.99 4.38* 3.69* 1.61* 1.15 Cluster 2	L16764	Heat shock protein 70-1	Hspala	13.98*	10.83*	16.25*	1.98	24.89*	83.48*	96.93*	6.70*	
NM 031971 Heat shock protein 70-1 Hspala 7.20* 6.42* 11.69* 1.55 NM 0.21012 Activating transcription factor 3 Atf3 2.18* 1.47 1.37 1.01 XB9966 NSP protein attachment protein alpha Napa 2.03* 1.08 1.20 5.20 4.26* 0.78 NM 012580 Heme oxygenase Hmoxi 1.48 1.98 2.40* 1.11 Cluster 2 Mili 1.02 5.41* 5.02* 1.71 M11794 Rat metallothionein-2 and metallothionein-1 genes Mt1a 0.09 4.38* 3.69* 1.41 J00750 Metallothionein 1 Mt1 1.06 6.03* 4.89* 1.61 1.04 1.30 3.35 2.30* 2.83* M86389 Heat shock protein 17 Hsp27 1.18 1.51 1.22* 1.64 3.10 1.32 0.33* 2.30* 2.40* M 01320 Backer Struten attacker insinibitor 1.A Cdbin 1.11 0.	Z75029	Hsp70.2 mRNA for heat shock protein 70	Hsp70.2	10.79*	10.81*	17.96*	2.76*	27.52*	80.88*	101.01*	10.92*	
NM 012912 Activating transcription factor 3 Atf3 2.18* 1.47 1.37 1.01 X89966 NSP protein attachment protein alpha Napa 2.03* 1.08 1.20 1.90 M0 12580 Heme oxygenase Hmoxi 1.08 1.08 1.20 1.90 M11794 Rat metallothionein-2 and metallothionein-1 genes Mtla 0.02 5.41* 5.02* 1.71 J00750 Metallothionein-2 and metallothionein-1 genes Mtla 0.06 5.43* 3.69* 1.61 J00750 Metallothionein-1 and metallothionein-1 genes Mtla 0.06 6.05* 4.89* 1.61 M65339 Heat shock protein T High 1.06 6.05* 4.89* 1.61 1.01 1.98* 3.36* M1031970 Heat shock protein 27 High 1.04 2.17* 1.44 1.37 1.30 3.35 2.38* MM 031970 Heat shock protein intipitore Call 1.31 2.06* 1.62 1.33	NM 031971	Heat shock protein 70-1	Hspala	7.20*	6.42*	11.69*	1.55		1			
X89968 NSF protein attachment protein alpha Napa 2.03* 1.08 1.20 1.90 NM 012580 Heme oxygenase Hmoxi 1.48 1.98 2.40* 1.11 M11794 Rat metallothionein-2 and metallothionein-1 genes Mt1a 0.09 4.38* 5.02* 1.71 M11794 Rat metallothionein-2 and metallothionein-1 genes Mt1a 0.09 4.38* 3.69* 1.41 J00759 Metallothionein 1 Mt1 1.06 6.05* 4.89* 1.41 J00759 Metallothionein 1 Mt1 1.06 6.05* 4.89* 1.14 1.30 3.35 2.30* 2.40* M1031970 Heat shock protein 27 Ht3p27 1.18 1.51 2.12* 1.20 1.64* 3.10 1.98* 3.38* M1023102 Direin decatorboxylase antizyme inhibitor O.22 1.82 1.14 1.30 3.35 2.30* 2.40* M1023256 Ultraviolet B radiation-activated UV96 UV96 0.44 0.79 1.44	NM 012912	Activating transcription factor 3	Atf3	2.18*	1.47	1.37	1.01	8.07*	5.20	4.26*	0.78	
NM 012580 Heme oxygenase Hmox1 1.48 1.98 2.40* 1.11 1.78 1.58 1.61* 1.15 Cluster 7 Mil1794 Rat metallothionein-2 and metallothionein-1 genes Mtl 1.02 5.41* 5.02* 1.71 J00750 Metallothionein 1 Mtl 0.06 6.05* 4.89* 1.61 0.71 10.16 5.07* 3.90* M10750 Metallothionein 1 Mtl 1.06 6.05* 4.89* 1.61 0.71 10.16 5.07* 3.90* M1031970 Metallothionein 1 Mtl 1.06 6.05* 4.89* 1.61 1.13 3.05 2.0* 2.3 M1031970 Heat shock protein 27 Hsp27 1.18 1.51 2.12* 1.26 1.33 3.35 2.39* 3.38* M212526 Ultraviole B radiation-activated UV96 OV4 2.12* 1.85 1.61* 1.17 0.38 5.00* 2.58* 1.03 M202016 Synaptotagmin 7 Ox7	X89968	NSF protein attachment protein alpha	Napa	2.03*	1.08	1.20	1.90			1.1		
Cluster 2 M11794 Rat metallothionein-1 genes Mt1a 1.02 5.41* 5.02* 1.71 J00750 Metallothionein-1 ad metallothionein-1 genes Mt1a 1.02 5.41* 5.02* 1.71 J00750 Metallothionein 1 Mt1 1.06 6.05* 4.89* 1.61 J00750 Metallothionein 1 Mt1 1.06 6.05* 4.89* 1.61 J00750 Metallothionein 1 Mt1 1.06 6.05* 4.89* 1.61 J00750 Metallothionein 2 Mt1s 1.54 2.27* 1.14 1.30 3.35 2.30* 2.40* MM 031270 Heat shock protein 27 Hsp27 1.18 1.51 2.12* 1.26 1.30 3.35 2.30* 2.40* MM 012026 Ultraviolet B radiation-activated UV96 UV96 0.94 2.12* 1.85 1.01 0.88 5.00* 2.58* 1.03 AB029342 TBP-interacing protein Tip20B Tip120B 1.18 2.01* 1.50 0.99 0.86 0.60 1.63* 3.91* 1.47 <td>NM 012580</td> <td>Heme oxygenase</td> <td>Hmox1</td> <td>1.48</td> <td>1.98</td> <td>2.40*</td> <td>1.11</td> <td>1.78</td> <td>1.58</td> <td>1.61*</td> <td>1.15</td>	NM 012580	Heme oxygenase	Hmox1	1.48	1.98	2.40*	1.11	1.78	1.58	1.61*	1.15	
M11794 Rat metallobionein-2 and metallobionein-1 genes Mt1a 1.02 5.41* 5.02* 1.71 0.71 10.16 5.07* 3.90* M11794 Rat metallobionein-2 and metallobinoein-1 genes Mt1a 0.09 4.38* 3.60* 1.41 J00750 Metallobinoein-1 and metallobinoein-1 genes Mt1a 0.06 6.05* 4.88* 1.61 0.79 13.54* 6.78* 2.83 M55534 Crystallin, alpha B Cryab 0.83 1.48 2.31* 1.21 0.79 13.54* 6.78* 2.83 M63399 Heat shock protein T7 Hsp27 1.01 1.54 2.27* 1.14 1.30 3.35 2.30* 2.40* NM 01970 Heat shock 27 kDa protein Hsp27 1.01 1.54 2.27* 1.44 1.37 U21252 Ultraviolet B radiation-activated UV96 UV96 0.94 2.12* 1.85 1.01 6.8* 5.00* 2.58* 1.03 M201050 Symptotage anizyme inhibitor Oazi 1.18 2.01* 1.50 0.99 0.38 0.10* 1.17	Cluster 2						es A			-		
M11794 Rat metallothionein-1 genes Mt1a 0.99 4.38* 3.69* 1.41 J00750 Metallothionein 1 Mt1 1.06 6.05* 4.89* 1.61 M55534 Crystallin, alpha B Cryab 0.83 1.48 2.31* 1.21 M6338 Heat shock protein 27 Hsp27 1.18 1.51 2.12* 1.64* 3.10 1.32.8* 3.38* M11794 Rat metallothionein-1 Mt1 1.06 6.05* 4.89* 1.61 M6338 Heat shock protein 27 Hsp27 1.18 1.51 2.12* 1.64* 3.10 3.35 2.30* 2.40* M011792 Ultraviolet B radiation-activated UV96 UV96 0.94 2.12* 1.85 1.01 B89983 Ornithine decarboxylase antizyme inhibitor Oazi 1.18 2.01* 1.50 0.99 0.80 1.09 1.11 0.30 B9983 Ornithine decarboxylase antizyme inhibitor Oazi 1.18 2.01* 1.20 1.31	M11794	Rat metallothionein-2 and metallothionein-1 genes	Mtla	1.02	5.41*	5.02*	1.71	0.71	10.16	5.07*	3.90*	
J00750 Metallothionein 1 Mt1 1.06 6.05* 4.89* 1.61 0.79 13.54* 6.78 2.83 M55354 Crystallin, alpha B Crya 0.83 1.48 2.21* 1.21 1.64* 3.10 1.98* 3.38* M633970 Heat shock protein 27 Hsp27 1.01 1.54 2.27* 1.14 JU2326 Ultraviolet B radiation-activated UV96 UV96 0.94 2.12* 1.28 1.01 1.30 3.35 2.30* 2.40* M203397 Iterations inhibitor 1A Cdkn1a 1.04 2.17* 1.44 1.30 3.35 2.30* 2.40* M20312 Orisitine decarboxylase antizyme inhibitor Cdkn1a 1.04 2.17* 1.44 1.37 0.38 0.90 1.11 0.38 M203125 Ornithine decarboxylase antizyme inhibitor Std7 0.97 2.00* 1.44 0.91 M101255 Early growth response 1 Egr1 2.42* 1.16 0.78 0.39* <t< td=""><td>M11794</td><td>Rat metallothionein-2 and metallothionein-1 genes</td><td>Mtla</td><td>0.99</td><td>4.38*</td><td>3.69*</td><td>1.41</td><td>1</td><td>-</td><td>a large and</td><td>Constants.</td></t<>	M11794	Rat metallothionein-2 and metallothionein-1 genes	Mtla	0.99	4.38*	3.69*	1.41	1	-	a large and	Constants.	
MS5534 Crystallin, alpha B Cryab 0.83 1.48 2.31* 1.21 1.64* 3.10 1.98* 3.38* M86389 Heat shock protein 27 Hsp27 1.01 1.54 2.27* 1.14 1.30 3.35 2.30* 2.40* W1031970 Heat shock protein 27 Kasso List 1.51 2.12* 1.64 3.10 1.98* 3.38* U20172 Ultraviole B radiation-activated UV96 UV96 0.94 2.12* 1.85 1.01 AB029342 TBP-interacting protein Tip120B Tip120B 1.13 2.06* 1.62 1.33 Bab29340 Ornithine decarboxylase antizyme inhibitor Oazi 1.18 2.01* 1.50 0.99 U20106 Synaptotagmin 7 Syr 0.97 2.00* 1.44 0.91 0.80 1.03 0.30* U101255 Berly growth response 1 Egr1 Syr 0.97 2.00* 1.44 0.91 MM 01255 Brinkitor, alpha Nrda1 2.02* 0.05 0.09* 0.38 0.46* 2.49 1.42 0.7	J00750	Metallothionein 1	Mt1	1.06	6.05*	4.89*	1.61	0.79	13.54*	6.78	2.83	
M86389 Heat shock protein 27 Hsp27 1.01 1.54 2.27* 1.14 NM 031970 Heat shock 27 kDa protein Hsp27 1.18 1.51 2.12* 1.26 U24174 Cyclin-dependent kinase inhibitor 1A Cdkn1a 1.04 2.17* 1.44 1.37 U12526 Ultraviolet B radiation-activated UV96 UV96 0.94 2.12* 1.85 1.01 AB029342 TBP-interacting protein Tip120B Tip120B 1.13 2.06* 1.62 1.33 D20106 Synaptotagmin 7 Syt7 0.97 2.00* 1.44 0.91 1.63* 3.91* 1.47 1.33 U20106 Synaptotagmin 7 Syt7 0.97 2.00* 1.44 0.91 1.65* 3.91* 1.47 1.33 U20155 Berly growth response 1 Egr1 2.42* 1.16 0.78 0.39* 1.64* 3.16* 5.61* 4.51 3.16* NM 017027 Myelin protein zero MPZ 0.20* 0.86 0.56 0.09* 3.46* 2.49 1.42 0.73 X6359	M55534	Crystallin, alpha B	Cryab	0.83	1.48	2.31*	1.21	1.64*	3.10	1.98*	3.38*	
NM 031970 Heat shock 27 kDa protein Hsp27 1.18 1.51 2.12* 1.26 U24174 Cyclin-dependent kinase inhibitor 1A Cdkn1a 1.04 2.17* 1.44 1.37 U12526 Ultraviolet B radiation-activated UV96 UV96 0.94 2.12* 1.85 1.01 AB029342 TBP-interacting protein Tip120B Tip120B 1.13 2.06* 1.62 1.33 D39983 Ornithine decarboxylase antizyme inhibitor Oazi 1.18 2.01* 1.50 0.99 U2016 Synaptotagmin 7 Syt7 0.97 2.00* 1.44 0.91 1.11 0.93 Cluster 3 Fos NM NA	M86389	Heat shock protein 27	Hsp27	1.01	1.54	2.27*	1.14	1.30	3.35	2.30*	2.40*	
U24174 Cyclin-dependent kinase inhibitor 1A Cdkn1a 1.04 2.17* 1.44 1.37 U12526 Ultraviolet B radiation-activated UV96 UV96 0.94 2.12* 1.85 1.01 AB029342 TBP-interacting protein Tip120B Tip120B 1.13 2.06* 1.62 1.33 D89983 Ornithine decarboxylase antizyme inhibitor Oazi 1.18 2.01* 1.50 0.99 0.88 5.00* 2.58* 1.03 D89983 Ornithine decarboxylase antizyme inhibitor Oazi 1.18 2.01* 1.50 0.99 0.80 1.09 1.11 0.33 Cluster 3 Fos fos NA	NM 031970	Heat shock 27 kDa protein	Hsp27	1.18	1.51	2.12*	1.26		÷	1 1	111	
U12526 Ultraviolet B radiation-activated UV96 UV96 0.94 2.12* 1.85 1.01 0.88 5.00* 2.58* 1.03 AB029342 TBP-interacting protein Tip120B Tip120B 1.13 2.06* 1.62 1.33 0.88 5.00* 2.58* 1.03 D89983 Omithine decarboxylase antizyme inhibitor Oazi 1.18 2.01* 1.50 0.99 0.80 1.63* 3.91* 1.47 1.33 U20106 Synaptotagmin 7 Syt7 0.97 2.00* 1.44 0.91 0.80 1.09 1.11 0.30 Cluster 3 Custer 4 1.03 1.05 0.80 1.09 1.11 0.50 M0 012551 Early growth response 1 Egr1 2.42* 1.16 0.78 0.39* 0.46* 2.50* 1.42 0.73 M0 012551 Early growth response 1 Egr1 2.42* 1.16 0.78 0.39* 0.71 Cluster 4 Inmediate early gene transcription factor NGFI-B Nr4a	U24174	Cyclin-dependent kinase inhibitor 1A	Cdknla	1.04	2.17*	1.44	1.37		-	1		
AB029342 TBP-interacting protein Tip120B Tip120B 1.13 2.06* 1.62 1.33 D89983 Ornithine decarboxylase antizyme inhibitor Oazi 1.18 2.01* 1.50 0.99 U20106 Synaptotagmin 7 Syd7 0.97 2.00* 1.44 0.91 0.80 1.09 1.11 0.93 Cluster 3 Fos fos NA <	U12526	Ultraviolet B radiation-activated UV96	UV96	0.94	2.12*	1.85	1.01	0.88	5.00*	2.58*	1.03	
D89983 Ornithine decarboxylase antizyme inhibitor Oazi 1.18 2.01* 1.50 0.99 1.63* 3.91* 1.47 1.33 U20106 Synaptotagmin 7 Syt7 0.97 2.00* 1.44 0.91 0.80 1.09 1.11 0.93 Cluster 3 Fos fos NA	AB029342	TBP-interacting protein Tip120B	Tip120B	1.13	2.06*	1.62	1.33				11.	
U20106 Synaptotagmin 7 Syt7 0.97 2.00* 1.44 0.91 0.80 1.09 1.11 0.93 Cluster 3 Fos fos NA NA <th< td=""><td>D89983</td><td>Ornithine decarboxylase antizyme inhibitor</td><td>Oazi</td><td>1.18</td><td>2.01*</td><td>1.50</td><td>0.99</td><td>1.63*</td><td>3.91*</td><td>1.47</td><td>1.33</td></th<>	D89983	Ornithine decarboxylase antizyme inhibitor	Oazi	1.18	2.01*	1.50	0.99	1.63*	3.91*	1.47	1.33	
Cluster 3 Fos fos NA NA NA NA NA NA NM 017259 B-cell translocation gene 2 BTG2 2.44* 1.03 1.05 0.80 1002551 Early growth response 1 Egr1 2.42* 1.16 0.78 0.39* 1002553 Protein tyrosine phosphatase, non-receptor type 16 Ptpn16 2.12* 1.27 1.11 0.51 NM 024388 Immediate early gene transcription factor NGFL-B Nr4a1 2.02* 1.02 0.88 0.71 Cluster 4 NM 017027 Myelin protein zero MPZ 0.20* 0.86 0.56 0.09* . 2.23* 3.61 1.80 0.85 NM 017037 Peripheral myelin protein 22 PMP22 0.52 0.91 0.69 0.43* 1.51 1.45 1.03 1.93* NM 013048 Tocopherol transfer protein alpha Tipa 1.03 0.33* <t< td=""><td>U20106</td><td>Synaptotagmin 7</td><td>Syt7</td><td>0.97</td><td>2.00*</td><td>1.44</td><td>0.91</td><td>0.80</td><td>1.09</td><td>1.11</td><td>0.93</td></t<>	U20106	Synaptotagmin 7	Syt7	0.97	2.00*	1.44	0.91	0.80	1.09	1.11	0.93	
Fos fos NA N	Cluster 3						1.20				·	
NM 017259 B-cell translocation gene 2 BTG2 2.44* 1.03 1.05 0.80 NM 012551 Early growth response 1 Egr1 2.42* 1.16 0.78 0.39* U02553 Protein tyrosine phosphatase, non-receptor type 16 Ptpn16 2.12* 1.27 1.11 0.51 NM 024388 Immediate early gene transcription factor NGFI-B Nr4a1 2.02* 0.80 0.36* 2.44* 1.02 0.89 0.71 X63594 NF kappa B inhibitor, alpha NrKbia 1.15 1.10 0.99 0.38 0.24 1.85 0.68 0.12 X63594 NF kappa B inhibitor, alpha NrKbia 1.15 1.10 0.99 0.38 0.24 1.85 0.68 0.12 X63594 NF kappa B inhibitor, alpha NrKbia 1.15 1.10 0.99 0.38 NM 013036 Fissue-type transglutaminase Tgm2 0.52 0.91 0.69 0.43* Cluster Tissue-type transglutaminase Tgm2 0.49* 0.97	B D Street	Fos	fos	NA	NA	NA	NA	13.16*	5.61*	4.51	3.16*	
NM 012551 Early growth response 1 Egrl 2.42* 1.16 0.78 0.39* 3.46* 2.49 1.42 0.73 U02553 Protein tyrosine phosphatase, non-receptor type 16 Ptpn16 2.12* 1.27 1.11 0.51 NM 043388 Immediate carly gene transcription factor NGFI-B Nr4al 2.02* 1.02 0.89 0.71 NM 017037 Wein protein zero MPZ 0.20* 0.86 0.56 0.09* 0.24 1.85 0.68 0.12 X63594 NF kappa B inhibitor, alpha Nfkbia 1.15 1.10 0.99 0.38 NM 017037 Peripheral myelin protein 22 PMP22 0.52 0.91 0.69 0.43* Z78279 Collagen, alpha1, type I Colla1 0.59 0.88 0.77 0.45* NM 013048 Tocopherol transfer protein alpha Ttpa 1.03 0.33* 0.40 1.09 M32509 Hemoglobin, beta Hbb 0.42* 0.52 0.80 0.72 M103048 <td>NM 017259</td> <td>B-cell translocation gene 2</td> <td>BTG2</td> <td>2.44*</td> <td>1.03</td> <td>1.05</td> <td>0.80</td> <td>1</td> <td></td> <td>0</td> <td></td>	NM 017259	B-cell translocation gene 2	BTG2	2.44*	1.03	1.05	0.80	1		0		
U02553 Protein tyrosine phosphatase, non-receptor type 16 Ptpn16 2.12* 1.27 1.11 0.51 NM 024388 Immediate early gene transcription factor NGFI-B Nr4al 2.02* 1.02 0.89 0.71 Cluster 4 X63594 NF kapa B inhibitor, alpha MPZ 0.20* 0.86 0.56 0.09* 0.24 1.85 0.68 0.12 X63594 NF kapa B inhibitor, alpha Nfkbia 1.15 1.10 0.99 0.38 0.24 1.85 0.68 0.12 X63594 NF kapa B inhibitor, alpha Nfkbia 1.15 1.10 0.99 0.38 0.24 1.80 0.85 NM 013036 Tissue-type transglutaminase Tgm2 0.59 0.88 0.77 0.45* NM 013048 Tocopherol transfer protein alpha Ttpa 1.03 0.33* 0.40 1.09 M32509 Hemoglobin, beta Hbb 0.42*	NM 012551	Early growth response 1	Egr1	2.42*	1.16	0.78	0.39*	3.46*	2.49	1.42	0.73	
NM 024388 Immediate early gene transcription factor NGFI-B Nr4al 2.02* 1.02 0.89 0.71 Cluster 4 . <td>U02553</td> <td>Protein tyrosine phosphatase, non-receptor type 16</td> <td>Ptpn16</td> <td>2.12*</td> <td>1.27</td> <td>1.11</td> <td>0.51</td> <td></td> <td></td> <td></td> <td></td>	U02553	Protein tyrosine phosphatase, non-receptor type 16	Ptpn16	2.12*	1.27	1.11	0.51					
Cluster 4 MPZ 0.20* 0.86 0.56 0.09* 0.24 1.85 0.68 0.12 X6394 NF kapa B inhibitor, alpha Nfkbia 1.15 1.10 0.99 0.38 0.24 1.85 0.68 0.12 X6394 NF kapa B inhibitor, alpha Nfkbia 1.15 1.10 0.99 0.38 0.23* 3.61 1.80 0.85 NM 017037 Peripheral myelin protein 22 PMP22 0.52 0.91 0.69 0.43* 0.45* NM 013046 Fissue-type transglutaminase Tgm2 0.49* 0.97 1.17 0.66 1.51 1.45 1.03 1.93* Cluster 5 Image 1.03 0.33* 0.40 1.09 1.51 1.45 1.03 1.93* M32509 Hemoglobin, beta Hbb 0.42* 0.52 0.80 0.72 M1084 Hemoglobin, beta Hbb 0.48* 0.56 0.57 0.85 AF306546 Soltuc carrier family 21, member 14 Slc2	NM 024388	Immediate early gene transcription factor NGFI-B	Nr4a1	2.02*	1.02	0.89	0.71					
NM 017027 Myelin protein zero MPZ 0.20° 0.86 0.56 0.09° 0.24 1.85 0.68 0.12 X63594 NF kapa B inhibitor, alpha Nfkbia 1.15 1.10 0.99 0.38 2.23° 3.61 1.80 0.85 NM 017037 Peripheral myelin protein 22 PMP2 0.52 0.91 0.69 0.43° Z78279 Collagen, alphal, type I Colla1 0.59 0.88 0.77 0.45° NM 013046 Fissue-type transglutaminase Tgm2 0.97 0.93° 0.97 1.17 0.66 1.51 1.45 1.03 1.93° M32509 Hemoglobin, beta Hbb 0.42° 0.52 0.80 0.72 M10844 Hemoglobin, beta Hbb 0.42° 0.52 0.80 0.72 M17084 Hemoglobin, beta Hbb 0.42° 0.52 0.80 0.72 M170133 Glycin carrier family 21, member 14 Slc21a14 0.69 0.47° 0.67 0.62 </td <td>Cluster 4</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>1</td>	Cluster 4										1	
X63594 NF kappa B inhibitor, alpha Nfkbia 1.15 1.10 0.99 0.38 2.23* 3.61 1.80 0.85 NM 017037 Peripheral myelin protein 22 PMP22 0.52 0.91 0.69 0.43* Z78279 Collagen, alphal, type I Colla1 0.59 0.88 0.77 0.45* NM 013036 Tissue-type transglutaminase Tgm2 0.49* 0.97 1.17 0.66 1.51 1.45 1.03 1.93* Cluster T Tgm2 0.49* 0.97 1.17 0.66 1.51 1.45 1.03 1.93* M32509 Hemoglobin, beta Hbb 0.42* 0.52 0.80 0.72 M1084 Hemoglobin, beta Hbb 0.44* 0.56 0.75 0.88 AF306546 Solute carrier family 21, member 14 Slc21a14 0.69 0.47* 0.62 NM 013133 Glycine receptor, alpha 1 subunit Girai 0.73 0.50* 0.57 0.85	NM 017027	Myelin protein zero	MPZ	0.20*	0.86	0.56	0.09*	0.24	1.85	0.68	0.12	
NM 017037 Peripheral myelin protein 22 PMP22 0.52 0.91 0.69 0.43* Z78279 Collagen, alpha1, type I Colla1 0.59 0.88 0.77 0.45* NM 019386 Tissue-type transglutaminase Tgm2 0.49* 0.97 1.17 0.66 1.51 1.45 1.03 1.93* Cluster 5 T Ttpa 1.03 0.33* 0.40 1.09 M32509 Hemoglobin, beta Hbb 0.42* 0.52 0.80 0.72 M17084 Hemoglobin, beta Hbb 0.43* 0.50 0.57 0.80 AF306546 Solute carrier family 21, member 14 Slc2 la14 0.69 0.47* 0.67 0.62 NM 01313 Glycine receptor, alpha 1 subunit Glra1 0.73 0.50* 0.57 0.85 2.78* 2.10* 1.27 0.72	X63594	NF kappa B inhibitor, alpha	Nfkbia	1.15	1.10	0.99	0.38	2.23*	3.61	1.80	0.85	
Z78279 Collagen, alpha1, type I Colla1 0.59 0.88 0.77 0.45* NM 019386 Tissue-type transglutaminase Tgm2 0.49* 0.97 1.17 0.66 1.51 1.45 1.03 1.93* Cluster 5 Image: Clu	NM 017037	Peripheral myelin protein 22	PMP22	0.52	0.91	0.69	0.43*					
NM 019386 Tissue-type transglutaminase Tgm2 0.49* 0.97 1.17 0.66 1.51 1.45 1.03 1.93* Cluster 5 NM 013048 Tocopherol transfer protein alpha Ttpa 1.03 0.33* 0.40 1.09 M32509 Hemoglobin, beta Hbb 0.42* 0.52 0.80 0.72 M17084 Hemoglobin, beta Hbb 0.48* 0.56 0.75 0.62 NM 01313 Glycin receptor, alpha 1 subunit Glra1 0.73 0.50* 0.57 0.85 2.78* 2.10* 1.27 0.72	Z78279	Collagen, alpha1, type I	Collal	0.59	0.88	0.77	0.45*					
Claster 5 NM 013048 Tocopherol transfer protein alpha Ttpa 1.03 0.33* 0.40 1.09 M32509 Hemoglobin, beta Hbb 0.42* 0.52 0.80 0.72 M17084 Hemoglobin, beta Hbb 0.48* 0.56 0.75 0.80 AF306546 Solute carrier family 21, member 14 Slc21a14 0.69 0.47* 0.62 MM 013133 Glycine receptor, alpha 1 subunit Giral 0.73 0.50* 0.55* 0.85 2.78* 2.10* 1.27 0.72	NM 019386	Tissue-type transglutaminase	Tgm2	0.49*	0.97	1.17	0.66	1.51	1.45	1.03	1.93*	
NM 013048 Tocopherol transfer protein alpha Ttpa 1.03 0.33* 0.40 1.09 M32509 Hemoglobin, beta Hbb 0.42* 0.52 0.80 0.72 M17084 Hemoglobin, beta Hbb 0.48* 0.56 0.75 0.80 AF306546 Solute carrier family 21, member 14 Slc21a14 0.69 0.47* 0.62 MM 013133 Glycin receptor, alpha 1 subunit Girail 0.73 0.50* 0.57* 0.85 2.78* 2.10* 1.27 0.72	Cluster 5		1041.08	22.00	4983		680	10-10 mg		2 1 -	1 7 m	
M32509 Hemoglobin, beta Hbb 0.42° 0.52 0.80 0.72 M17084 Hemoglobin, beta Hbb 0.48° 0.56 0.75 0.80 AF306546 Solute carrier family 21, member 14 Slc21a14 0.69 0.47° 0.67 0.62 NM 013133 Glycine receptor, alpha 1 subunit Gira1 0.73 0.50° 0.57 0.85 2.78° 2.10° 1.27 0.72	NM 013048	Tocopherol transfer protein alpha	Ttpa	1.03	0.33*	0.40	1.09					
M17084 Hemoglobin, beta Hbb 0.48° 0.56 0.75 0.80 AF306546 Solute carrier family 21, member 14 Slc21a14 0.69 0.47° 0.67 0.62 NM 013133 Glycine receptor, alpha 1 subunit Glra1 0.73 0.50° 0.57 0.85 2.78° 2.10° 1.27 0.72	M32509	Hemoglobin, beta	Hbb	0.42*	0.52	0.80	0.72					
AF306546 Solute carrier family 21, member 14 Slc21a14 0.69 0.47* 0.67 0.62 NM 013133 Glycine receptor, alpha 1 subunit Glra1 0.73 0.50* 0.57 0.85 2.78* 2.10* 1.27 0.72	M17084	Hemoglobin, beta	Hbb	0.48*	0.56	0.75	0.80					
NM 013133 Glycine receptor, alpha 1 subunit Gira1 0.73 0.50* 0.57 0.85 2.78* 2.10* 1.27 0.72	AF306546	Solute carrier family 21, member 14	Slc21a14	0.69	0.47*	0.67	0.62					
	NM 013133	Glycine receptor, alpha 1 subunit	Glra1	0.73	0.50*	0.57	0.85	2.78*	2.10*	1.27	0.72	

ì

1.





.



